研究者詳細 - 室橋光太

所属以外の情報はresearchmapへの登録情報を転載しています。

写真a

ムロハシ　コウタ

室橋光太

Kota Murohashi

所属

医学部医学科呼吸器病学助教

外部リンク

学位

博士（医学）（ 2021年8月横浜市立大学）

研究キーワード

間質性肺炎

研究分野

ライフサイエンス / 呼吸器内科学

論文

Rapid detection of non-small cell lung cancer driver mutations using droplet digital polymerase chain reaction analysis of bronchial washings: a prospective multicenter study. 国際誌

Kohei Somekawa, Nobuaki Kobayashi, Satoshi Nagaoka, Kenichi Seki, Yukihito Kajita, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Ryo Nagasawa, Kota Murohashi, Hiroaki Fuji, Shuhei Teranishi, Ken Tashiro, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Makoto Kudo, Takeshi Kaneko

Translational lung cancer research 14 ( 2 ) 353 - 362 2025年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Molecular profiling of non-small cell lung cancer (NSCLC) is crucial for personalized treatment, but obtaining adequate tumor tissue can be challenging. This study evaluated the utility of droplet digital polymerase chain reaction (ddPCR) analysis of bronchial washings (BWs) and serum for detecting driver oncogene mutations in NSCLC patients, comparing its performance to standard tissue genotyping methods. METHODS: In this prospective, multicenter study conducted at two university hospitals in Yokohama, Japan, 73 treatment-naïve NSCLC patients underwent bronchoscopy with BW collection and blood sampling between October 2022 and April 2024. ddPCR was performed on BW and serum samples to detect epidermal growth factor receptor (EGFR; L858R, exon 19 deletions, G719X), KRAS (G12/13), and BRAF (V600E) mutations. Results were compared with standard tissue genotyping methods, including AmoyDx and Oncomine Dx Target Test (DxTT) assays. Turnaround time (TAT) for results was also assessed. The study protocol was approved by the institutional review boards, and all participants provided informed consent. RESULTS: ddPCR analysis of BW samples showed high concordance with tissue genotyping, detecting EGFR mutations in 31.5% of cases (identical to tissue). For common EGFR mutations (L858R and exon 19 deletions), BW genotyping demonstrated 100% sensitivity and 98.0% specificity compared to tissue. TAT was significantly shorter for BW ddPCR compared to tissue genotyping (4.4±1.8 vs. 20.4±7.7 days, P<0.001). Serum ddPCR showed lower sensitivity (7.8% vs. 33.3% for EGFR mutations) compared to tissue genotyping, with detection associated with the presence of bone metastases. KRAS and BRAF mutations were detected at similar rates in BW and tissue samples, but at lower rates in serum. CONCLUSIONS: ddPCR analysis of BWs demonstrates high accuracy and rapid TAT for detecting common driver mutations in NSCLC. This approach represents a promising alternative to tissue biopsy for molecular profiling, potentially expediting treatment decisions. While serum ddPCR showed limited utility, it may complement tissue genotyping in specific clinical scenarios.

DOI： 10.21037/tlcr-24-772

PubMed

researchmap
Geographic and economic influences on benralizumab prescribing for severe asthma in Japan. 国際誌

Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko

Scientific reports 14 ( 1 ) 15190 - 15190 2024年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma. In Japan, geographic disparities in asthma outcomes suggest differential prescribing and access. This study aimed to quantify regional prescribing variations for benralizumab nationwide. Using Japan's National Database (NDB) of insurance claims (2009-2019), benralizumab standardized claim ratios (SCRs) were calculated for 47 prefectures. Correlations between SCRs and other biologics' SCRs, economic variables like average income, and physician densities were evaluated through univariate analysis and multivariate regressions. Income-related barriers to optimal prescribing were examined. Wide variation emerged in benralizumab SCRs, from 40.1 to 184.2 across prefectures. SCRs strongly correlated with omalizumab (r = 0.61, p < 0.00001) and mepolizumab (r = 0.43, p = 0.0024). Average monthly income also positively correlated with benralizumab SCRs (r = 0.45, p = 0.0016), whereas lifestyle factors were insignificant. Respiratory specialist density modestly correlated with SCRs (r = 0.29, p = 0.047). In multivariate regressions, average income remained the most robust predictor (B = 0.74, p = 0.022). Benralizumab SCRs strongly associate with income metrics more than healthcare infrastructure/population factors. Many regions show low SCRs, constituting apparent prescribing gaps. Access barriers for advanced asthma therapies remain inequitable among Japan's income strata. Addressing affordability alongside specialist allocation can achieve better prescribing quality and asthma outcomes.

DOI： 10.1038/s41598-024-65407-4

PubMed

researchmap
リツキシマブ投与後の難治性COVID-19肺炎に対してヒト免疫グロブリン療法を行った一例

山田寛士, 久保創介, 村岡傑, 大津佑希子, 平田萌々, 田中克志, 長澤遼, 藤井裕明, 青木絢子, 室橋光太, 渡邉恵介, 堀田信之, 原悠, 小林信明, 金子猛

神奈川医学会雑誌 51 ( 2 ) 143 - 143 2024年7月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
HLA-DQA1*01:03 and DQB1*06:01 are risk factors for severe COVID-19 pneumonia. 国際誌

Katsushi Tanaka, Akira Meguro, Yu Hara, Lisa Endo, Ami Izawa, Suguru Muraoka, Ayami Kaneko, Kohei Somekawa, Momo Hirata, Yukiko Otsu, Hiromi Matsumoto, Ryo Nagasawa, Sosuke Kubo, Kota Murohashi, Ayako Aoki, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Hideaki Kato, Nobuaki Kobayashi, Ichiro Takeuchi, Atsushi Nakajima, Hidetoshi Inoko, Nobuhisa Mizuki, Takeshi Kaneko

HLA 104 ( 1 ) e15609 2024年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

The clinical spectrum of COVID-19 includes a wide range of manifestations, from mild symptoms to severe pneumonia. HLA system plays a pivotal role in immune responses to infectious diseases. The purpose of our study was to investigate the association between HLA and COVID-19 severity in a Japanese population. The study included 209 Japanese COVID-19 patients aged ≥20 years. Saliva samples were collected and used to determine the HLA genotype by HLA imputation through genome-wide association analyses. The association between HLA genotype and COVID-19 severity was then evaluated. The allele frequency was compared between patients with respiratory failure (severe group: 91 cases) and those without respiratory failure (non-severe group: 118 cases), categorising the data into three time periods: pre-Omicron epidemic period, Omicron epidemic period, and total period of this study (from January 2021 to May 2023). In comparing the severe and non-severe groups, the frequencies of the HLA-DQA1*01:03 (35.1% vs. 10.5%, odds ratio [OR] = 4.57, corrected p [pc] = 0.041) and -DQB1*06:01 (32.4% vs. 7.9%, OR = 5.54, pc = 0.030) alleles were significantly higher in the severe group during the pre-Omicron epidemic period. During the Omicron epidemic period, HLA-DQB1*06 (32.4% vs. 7.9%, OR = 5.54, pc = 0.030) was significantly higher in the severe group. During total period of this study, HLA-DQA1*01:03 (30.2% vs. 14.4%, OR = 2.57, corrected pc = 0.0013) and -DQB1*06:01 (44.5% vs. 26.7%, OR = 2.20, pc = 0.013) alleles were significantly higher in the severe group. HLA-DQB1*06:01 and -DQA1*01:03 were in strong linkage disequilibrium with each other (r2 = 0.91) during total period of this study, indicating that these two alleles form a haplotype. The frequency of the HLA-DQA1*01:03-DQB1*06:01 in the severe group was significantly higher than in the non-severe group during pre-Omicron epidemic period (32.4% vs. 7.9%, OR = 5.59, pc = 0.00072), and total period of this study (28.6% vs. 13.1%, OR = 2.63, pc = 0.0013). During Omicron epidemic period, the haplotype did not demonstrate statistical significance, although the odds ratio indicated a value greater 1. Frequencies of the HLA-DQA1*01:03 and -DQB1*06:01 alleles were significantly higher in severe COVID-19 patients, suggesting that these alleles are risk factors for severe COVID-19 pneumonia in the Japanese population.

DOI： 10.1111/tan.15609

PubMed

researchmap
インターフェロンγ遊離試験と活動性結核患者の死亡リスク

小林信明, 村岡傑, 平田萌々, 大津佑季子, 染川弘平, 金子彩美, 松本大海, 田中克志, 久保創介, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 原悠, 金子猛

神奈川医学会雑誌 51 ( 2 ) 147 - 147 2024年7月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
外科的切除後に再発した肺クリプトコッカス症の1例

小俣沙織, 渡邉恵介, 村岡傑, 大津佑希子, 平田萌々, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 堀田信之, 原悠, 小林信明, 金子猛

神奈川医学会雑誌 51 ( 2 ) 147 - 148 2024年7月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
Whole-Genome Sequencing Predicting Phenotypic Antitubercular Drug Resistance: Meta-analysis. 国際誌

Yoichi Tagami, Nobuyuki Horita, Megumi Kaneko, Suguru Muraoka, Nobuhiko Fukuda, Ami Izawa, Ayami Kaneko, Kohei Somekawa, Chisato Kamimaki, Hiromi Matsumoto, Katsushi Tanaka, Kota Murohashi, Ayako Aoki, Hiroaki Fujii, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko

The Journal of infectious diseases 229 ( 5 ) 1481 - 1492 2024年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: For simultaneous prediction of phenotypic drug susceptibility test (pDST) for multiple antituberculosis drugs, the whole genome sequencing (WGS) data can be analyzed using either a catalog-based approach, wherein 1 causative mutation suggests resistance, (eg, World Health Organization catalog) or noncatalog-based approach using complicated algorithm (eg, TB-profiler, machine learning). The aim was to estimate the predictive ability of WGS-based tests with pDST as the reference, and to compare the 2 approaches. METHODS: Following a systematic literature search, the diagnostic test accuracies for 14 drugs were pooled using a random-effect bivariate model. RESULTS: Of 779 articles, 44 with 16 821 specimens for meta-analysis and 13 not for meta-analysis were included. The areas under summary receiver operating characteristic curve suggested test accuracy was excellent (0.97-1.00) for 2 drugs (isoniazid 0.975, rifampicin 0.975), very good (0.93-0.97) for 8 drugs (pyrazinamide 0.946, streptomycin 0.952, amikacin 0.968, kanamycin 0.963, capreomycin 0.965, para-aminosalicylic acid 0.959, levofloxacin 0.960, ofloxacin 0.958), and good (0.75-0.93) for 4 drugs (ethambutol 0.926, moxifloxacin 0.896, ethionamide 0.878, prothionamide 0.908). The noncatalog-based and catalog-based approaches had similar ability for all drugs. CONCLUSIONS: WGS accurately identifies isoniazid and rifampicin resistance. For most drugs, positive WGS results reliably predict pDST positive. The 2 approaches had similar ability. CLINICAL TRIALS REGISTRATION: UMIN-ID UMIN000049276.

DOI： 10.1093/infdis/jiad480

PubMed

researchmap
Improved diagnostic accuracy with three lung tumor markers compared to six-marker panel. 国際誌

Ami Izawa, Yu Hara, Nobuyuki Horita, Suguru Muraoka, Megumi Kaneko, Ayami Kaneko, Kohei Somekawa, Momo Hirata, Yukiko Otsu, Hiromi Matsumoto, Ryo Nagasawa, Katsushi Tanaka, Sousuke Kubo, Kota Murohashi, Ayako Aoki, Hiroaki Fujii, Keisuke Watanabe, Nobuaki Kobayashi, Kenji Miura, Hideaki Nakajima, Takeshi Kaneko

Translational lung cancer research 13 ( 3 ) 503 - 511 2024年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Combining multiple tumor markers increases sensitivity for lung cancer diagnosis in the cost of false positive. However, some would like to check as many as tumor markers in the fear of missing cancer. We though to propose a panel of fewer tumor markers for lung cancer diagnosis. METHODS: Patients with suspected lung cancer who simultaneously underwent all six tests [carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA), squamous cell carcinoma-associated antigen (SCC), neuron-specific enolase (NSE), pro-gastrin-releasing peptide (ProGRP), and sialyl Lewis-X antigen (SLX)] were included. Tumor markers with significant impact on the lung cancer in a logistic regression model were included in our panel. Area under the curve (AUC) was compared between our panel and the panel of all six. RESULTS: We included 1,733 [median 72 years, 1,128 men, 605 women, 779 (45%) confirmed lung cancer]. Logistic regression analysis suggested CEA, CYFRA, and NSE were independently associated with the lung cancer diagnosis. The panel of these three tumor markers [AUC =0.656, 95% confidence interval (CI): 0.630-0.682, sensitivity 0.650, specificity 0.662] had better (P<0.001) diagnostic performance than six tumor markers (AUC =0.575, 95% CI: 0.548-0.602, sensitivity 0.829, specificity 0.321). CONCLUSIONS: Compared to applying all six markers (at least one marker above the upper limit of normal), the panel with three markers (at least one marker above the upper limit of normal) led to a better predictive value by lowering the risk of false positives.

DOI： 10.21037/tlcr-23-855

PubMed

researchmap
びまん性肺疾患診断線維化性間質性肺炎急性増悪における血清マクロファージ活性化マーカーの臨床意義

井澤亜美, 原悠, 村岡傑, 平田萌々, 大津佑希子, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 184 - 184 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
抗線維化薬を使用している間質性肺疾患患者における蜂巣肺と予後の関連性について

長澤遼, 原悠, 室橋光太, 平田萌々, 大津佑希子, 渡邉恵介, 藤井裕明, 青木絢子, 田中克志, 久保創介, 村岡傑, 松本大海, 金子彩美, 井澤亜美, 染川弘平, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 367 - 367 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
中枢気道粘液栓スコア,気道樹所見,気道内体積の変化と病勢が連動したdupilumab使用重症喘息の一例

高安笙太, 原悠, 室橋光太, 長澤遼, 藤井裕明, 大津佑希子, 平田萌々, 井澤亜美, 上田傑, 田中克志, 久保創介, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 397 - 397 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
GINA step別にみる気管支喘息患者における低肺機能に影響する因子の検討

渡邉恵介, 村岡傑, 平田萌々, 大津佑希子, 井澤亜美, 金子彩美, 染川弘平, 松本大海, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 堀田信之, 原悠, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 327 - 327 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
進展型小細胞肺癌におけるCBDCA+ETP+ATZの有用性に関する検討

久保創介, 村岡傑, 大津佑希子, 染川弘平, 平田萌々, 松本大海, 金子彩美, 田中克志, 室橋光太, 藤井裕明, 渡邉恵介, 原悠, 小林信明, 山本昌樹, 工藤誠, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 329 - 329 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
当院における線維化性間質性肺疾患に対する抗線維化薬使用実態調査

大津佑希子, 原悠, 小林信明, 堀田信之, 渡邉恵介, 青木絢子, 藤井裕明, 室橋光太, 久保創介, 田中克志, 長澤遼, 平田萌々, 染川弘平, 金子彩美, 井澤亜美, 村岡傑, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 316 - 316 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
当院における閉塞性肺疾患患者へのSingle-inhaler triple therapy(SITT)使用実態調査

井澤亜美, 原悠, 村岡傑, 平田萌々, 大津佑希子, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 325 - 325 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患における末梢血中単球数と予後の予測についての臨床解析

平田萌々, 原悠, 村岡傑, 大津佑希子, 井澤亜美, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 287 - 287 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
進行期非小細胞肺癌における気管支洗浄液を用いたDroplet Digital PCR(ddPCR)法のEGFR遺伝子変異検出の比較

染川弘平, 小林信明, 村岡傑, 大津佑希子, 平田萌々, 井澤亜美, 金子彩美, 松本大海, 長澤遼, 久保創介, 田中克志, 室橋光太, 青木絢子, 藤井裕明, 渡邉恵介, 堀田信之, 原悠, 工藤誠, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 307 - 307 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
当院における非小細胞肺癌のEGFR遺伝子スクリーニング成功率と変異陽性率

東野裕生, 染川弘平, 小林信明, 村岡傑, 大津佑希子, 平田萌々, 井澤亜美, 金子彩美, 田中克志, 久保創介, 松本大海, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 原悠, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 265 - 265 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
末梢血単球数の変動と間質性肺疾患予後との関連性の検討単施設後ろ向きコホート研究

平田萌々, 原悠, 村岡傑, 大津佑希子, 井澤亜美, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 241 - 241 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
Single-inhaler triple therapy(SITT)使用閉塞性肺疾患患者のTreatable traitsの臨床的意義について

長澤遼, 原悠, 室橋光太, 平田萌々, 大津佑希子, 渡邉恵介, 藤井裕明, 青木絢子, 田中克志, 久保創介, 村岡傑, 松本大海, 金子彩美, 井澤亜美, 染川弘平

日本呼吸器学会誌 13 ( 増刊 ) 252 - 252 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
非小細胞肺癌分子標的治療 PET画像と臨床情報を用いたマルチモーダル深層学習による,肺癌に対するEGFR-TKI治療の予後予測モデルの構築

松本大海, 小林信明, 金子彩美, 染川弘平, 村岡傑, 平田萌々, 大津佑希子, 井澤亜美, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 塚田信之, 原悠, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 190 - 190 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
腫瘍免疫療法・予後予測因子 Pembrolizumabの治療効果予測因子の探索的検討データベース解析の妥当性の検証

福嶋太一, 松本大海, 小林信明, 染川弘平, 金子彩美, 村岡傑, 平田萌々, 大津佑希子, 井澤亜美, 久保創介, 田中克志, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 原悠, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 209 - 209 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
呼吸器感染症 COVID-19 COVID-19の重症化と関連する遺伝的要因の解明

田中克志, 目黒明, 原悠, 村岡傑, 久保創介, 長澤遼, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 小林信明, 猪子英俊, 水木信久, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 176 - 176 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases. 国際誌

Momo Hirata, Yu Hara, Hiroaki Fujii, Kota Murohashi, Yusuke Saigusa, Shiqi Zhao, Miyu Kobayashi, Ryo Nagasawa, Yoichi Tagami, Ami Izawa, Yukiko Otsu, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko

BMC pulmonary medicine 24 ( 1 ) 16 - 16 2024年1月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The ILD-GAP scoring system is known to be useful in predicting prognosis in patients with interstitial lung disease (ILD). An elevated monocyte count was associated with increased risks of IPF poor prognosis. We examined whether the ILD-GAP scoring system combined with the monocyte ratio (ILD-GAPM) is superior to the conventional ILD-GAP model in predicting ILD prognosis. METHODS: In patients with ILD treated between April 2013 and April 2017, we were retrospectively assessed the relationships between baseline clinical parameters, including age, sex, Charlson Comorbidity Index score (CCIS), ILD diagnosis, blood biomarkers, pulmonary function test results, and disease outcomes. In ILD patients were included idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (iNSIP), collagen vascular disease-related interstitial pneumonia (CVD-IP), chronic hypersensitivity pneumonitis (CHP), and unclassifiable ILD (UC-ILD). We also assessed the ability to predict prognosis was compared between the ILD-GAP and ILD-GAPM models. RESULTS: A total of 179 patients (mean age, 73 years) were assessed. All of them were taken pulmonary function test, including percentage predicted diffusion capacity for carbon monoxide. ILD patients included 56 IPF cases, 112 iNSIP and CVD-IP cases, 6 CHP cases and 5 UC-ILD cases. ILD-GAPM provided a greater area under the receiver-operating characteristic curve (0.747) than ILD-GAP (0.710) for predicting 3-year ILD-related events. Furthermore, the log-rank test showed that the Kaplan-Meier curves in ILD-GAPM were significantly different by stage (P = 0.015), but not by stage in ILD-GAP (P = 0.074). CONCLUSIONS: The ILD-GAPM model may be a more accurate predictor of prognosis for ILD patients than the ILD-GAP model.

DOI： 10.1186/s12890-023-02833-6

PubMed

researchmap
結核治療におけるピラジナミド使用の地域差と関連する因子の検討

松本大海, 小林信明, 福田信彦, 金子彩美, 上田傑, 金子恵, 染川弘平, 井澤亜美, 神巻千聡, 田中克志, 室橋光太, 藤井裕明, 青木絢子, 田上陽一, 渡邉恵介, 堀田信之, 原悠, 金子猛

神奈川医学会雑誌 51 ( 1 ) 111 - 112 2024年1月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma. 国際誌

Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko

European clinical respiratory journal 11 ( 1 ) 2384173 - 2384173 2024年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited. METHODS: This clinical study was a multicentre, retrospective, observational study at two hospitals. Patients aged ≥18 years diagnosed with severe asthma treated with benralizumab were included. Elderly patients were defined as those aged 70 years or older. Efficacy and safety were then analyzed in elderly and non-elderly patients. The primary endpoints were the annual number of asthma exacerbations for efficacy and the discontinuation rate due to adverse events for safety. RESULTS: Between August 2016 and October 2022, 61 patients were enrolled; 10 patients were excluded, and 51 (22 elderly, 29 non-elderly) patients were analyzed. In elderly patients, the annual number of asthma exacerbations before treatment with benralizumab (pre-benralizumab) was 3.78, and the number during treatment with benralizumab was 1.26, a decrease of 2.52 (95% confidence interval [CI], 1.3 to 3.74, p < 0.001). In non-elderly patients, the annual number of asthma exacerbation in the pre-benralizumab period was 3.24, and during treatment with benralizumab it was 0.68, a decrease of 2.56 (95% CI, 1.3 to 3.82, p < 0.001). There was no significant difference in discontinuation due to treatment-related adverse events (elderly vs non-elderly, 2 (9%) vs 0 (0%), p = 0.18). CONCLUSION: Benralizumab reduced the annual number of asthma exacerbations and was well tolerated in elderly patients.

DOI： 10.1080/20018525.2024.2384173

PubMed

researchmap
High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse. 国際誌

Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayashi, Yuuki Higashino, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Kohei Somekawa, Ayami Kaneko, Ryo Nagasawa, Sousuke Kubo, Katsushi Tanaka, Kota Murohashi, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko

PloS one 19 ( 8 ) e0299760 2024年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved outcomes in cancer treatment but are also associated with adverse events and financial burdens. Identifying accurate biomarkers is crucial for determining which patients are likely to benefit from ICIs. Current markers, such as PD-L1 expression and tumor mutation burden, exhibit limited predictive accuracy. This study utilizes a Clinical Data Warehouse (CDW) to explore the prognostic significance of novel blood-based factors, such as the neutrophil-to-lymphocyte ratio and red cell distribution width (RDW), to enhance the prediction of ICI therapy benefit. METHODS: This retrospective study utilized an exploratory cohort from the CDW that included a variety of cancers to explore factors associated with pembrolizumab treatment duration, validated in a non-small cell lung cancer (NSCLC) patient cohort from electronic medical records (EMR) and CDW. The CDW contained anonymized data on demographics, diagnoses, medications, and tests for cancer patients treated with ICIs between 2017-2022. Logistic regression identified factors predicting ≤2 or ≥5 pembrolizumab doses as proxies for progression-free survival (PFS), and Receiver Operating Characteristic analysis was used to examine their predictive ability. These factors were validated by correlating doses with PFS in the EMR cohort and re-testing their significance in the CDW cohort with other ICIs. This dual approach utilized the CDW for discovery and EMR/CDW cohorts for validating prognostic biomarkers before ICI treatment. RESULTS: A total of 609 cases (428 in the exploratory cohort and 181 in the validation cohort) from CDW and 44 cases from EMR were selected for study. CDW analysis revealed that elevated red cell distribution width (RDW) correlated with receiving ≤2 pembrolizumab doses (p = 0.0008), with an AUC of 0.60 for predicting treatment duration. RDW's correlation with PFS (r = 0.80, p<0.0001) and its weak association with RDW (r = -0.30, p = 0.049) were confirmed in the EMR cohort. RDW also remained significant in predicting short treatment duration across various ICIs (p = 0.0081). This dual methodology verified pretreatment RDW elevation as a prognostic biomarker for shortened ICI therapy. CONCLUSION: This study suggests the utility of CDWs in identifying prognostic biomarkers for ICI therapy in cancer treatment. Elevated RDW before treatment initiation emerged as a potential biomarker of shorter therapy duration.

DOI： 10.1371/journal.pone.0299760

PubMed

researchmap
Serum heme oxygenase-1 as a prognostic biomarker in patients with acute exacerbation of interstitial lung disease. 国際誌

Yoichi Tagami, Yu Hara, Kota Murohashi, Ryo Nagasawa, Hiroaki Fujii, Ami Izawa, Aya Yabe, Yusuke Saigusa, Miyu Kobayashi, Masafumi Shiida, Momo Hirata, Yukiko Otsu, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko

Scientific reports 13 ( 1 ) 22639 - 22639 2023年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Serum heme oxygenase (HO)-1 level has been reported as a clinically reliable diagnostic biomarker for acute exacerbation of interstitial lung disease (ILD); however, its utility for predicting mortality among these patients is unclear. Serum HO-1 levels of patients newly diagnosed with acute exacerbation of ILD were measured at the time of initiating steroid pulse therapy. The relationship between serum HO-1 and various other serum biomarkers, change in HRCT findings, and disease prognosis at 12 weeks after diagnosis of acute exacerbation was evaluated in 51 patients, of whom 17 (33%) had idiopathic pulmonary fibrosis (IPF). Serum HO-1 was higher in patients with acute exacerbation of IPF than in patients with acute exacerbation of other ILDs. Serum HO-1 levels were higher in patients who died within these 12 weeks than in survivors. Among age, sex, comorbidities, IPF diagnosis, HRCT findings, and blood biomarkers, serum HO-1 was a primary predictor of 12-week mortality. In 41 patients who underwent repeat HRCT, serum HO-1 was higher in patients with honeycomb progression than in those without. Serum HO-1 measurement could be useful for evaluating disease mortality and morbidity of patients with acute exacerbation of ILDs.

DOI： 10.1038/s41598-023-49342-4

PubMed

researchmap
tepotinibによる薬剤性肺障害を疑った1例

村岡傑, 小林信明, 平田萌々, 大津佑希子, 井澤亜美, 染川弘平, 金子彩美, 松本大海, 室橋光太, 田中克志, 久保創介, 長澤遼, 藤井裕明, 青木絢子, 渡邊恵介, 堀田信之, 原悠, 金子猛

気管支学 45 ( 6 ) 436 - 436 2023年11月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器内視鏡学会

researchmap
非小細胞肺癌のEGFR遺伝子変異検出におけるOncomine DxTTとCobas EGFR v2.0の比較

東野裕生, 染川弘平, 小林信明, 村岡傑, 井澤亜美, 大津佑希子, 金子彩美, 田中克志, 松本大海, 長澤遼, 久保創介, 室橋光太, 藤井裕明, 渡邉恵介, 堀田信之, 原悠, 金子猛

日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 184回・256回 23 - 23 2023年9月

　詳細を見る

記述言語：日本語出版者・発行元：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会

researchmap
アレルギー・免疫疾患:臨床課題と希少症例気管支拡張症における好酸球表現型の臨床的意義(Clinical significance of eosinophilic phenotype in bronchiectasis)

小林信明, 福田信彦, 村岡傑, 井澤亜美, 金子彩美, 室橋光太, 田中克志, 青木絢子, 渡邉恵介, 堀田信之, 原悠, 金子猛

アレルギー 72 ( 6-7 ) 891 - 891 2023年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
＜Editors' Choice＞ Comparison of clinical features between patients with acute exacerbation of idiopathic interstitial pneumonia and collagen vascular disease-associated interstitial pneumonia.

Yuki Kata, Yu Hara, Kota Murohashi, Yusuke Saigusa, Ryo Nagasawa, Yoichi Tagami, Hiroaki Fujii, Ayako Aoki, Yurika Nishikawa, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko

Nagoya journal of medical science 85 ( 3 ) 602 - 611 2023年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Acute exacerbation (AE) of interstitial pneumonia (IP) shows poor prognosis, due to the typical histological pattern of diffuse alveolar damage superimposed upon lung fibrosis. The previous reports comparing clinical features between AE of idiopathic interstitial pneumonias (IIPs) and those of IPs with known etiology are limited. We retrospectively compared clinical parameters including age, sex, Charlson Comorbidity Index score (CCIS), blood biomarkers at diagnosis of AE, treatment, and 3-month mortality between patients with AE of IIPs and collagen vascular disease-associated interstitial pneumonia (CVD-IP). We assessed 85 patients, comprising 66 patients with AE of IIPs (78%) and 19 patients with AE of CVD-IP (22%). The least absolute shrinkage and selection operator regression selected CCIS (hazard ratio, 1.281; 95% confidence interval, 1.055-1.556; P = 0.012) and log serum lactate dehydrogenase (LDH) (hazard ratio, 6.267; 95% confidence interval, 2.172-18.085; P < 0.001) as significant predictors of 3-month mortality among these patients. Also, the adjusted survival curves using sex, CCIS, and serum LDH showed no significant differences between these two groups. In conclusion, among AE patients, CCIS and serum LDH level may be more important prognostic factors for 3-month mortality rather than two classification of IP subtypes: IIPs and CVD-IP.

DOI： 10.18999/nagjms.85.3.602

PubMed

researchmap
結核治療におけるピラジナミド使用の地域差と関連する因子の検討

松本大海, 小林信明, 福田信彦, 金子彩美, 上田傑, 金子恵, 染川弘平, 井澤亜美, 神巻千聡, 田中克志, 室橋光太, 藤井裕明, 青木絢子, 田上陽一, 渡邉恵介, 堀田信之, 原悠, 金子猛

神奈川医学会雑誌 50 ( 2 ) 130 - 130 2023年7月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
活動性結核における好中球リンパ球比の意義

小林信明, 村岡傑, 金子恵, 井澤亜美, 神巻千聡, 田中克志, 田上陽一, 室橋光太, 青木絢子, 渡邊恵介, 堀田信之, 原悠, 金子猛

結核 98 ( 4 ) 130 - 130 2023年6月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本結核・非結核性抗酸菌症学会

researchmap
Severe multivessel coronary vasospasm in a patient with coronavirus disease 2019.

Mai Azuma, Shingo Kato, Kota Murohashi, Kazuki Fukui, Daisuke Utsunomiya, Hideya Kitamura, Eri Hagiwara, Takashi Ogura

Journal of cardiology cases 28 ( 4 ) 147 - 9 2023年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

UNLABELLED: We present the case of a 65-year-old male with multivessel coronary spasm presumably related to coronavirus disease 2019 (COVID-19). Acetylcholine coronary angiogram and cardiac magnetic resonance imaging were used for the diagnosis. As the precise pathophysiology of myocardial injury by COVID-19 remains unclear, the multimodality approach may contribute to the accurate diagnosis. LEARNING OBJECTIVE: Myocardial involvement by severe acute respiratory syndrome coronavirus 2 infection is related to various pathologies. It is important to evaluate the degrees of cardiac damage and make a diagnosis by multimodality imaging especially with cardiac magnetic resonance.

DOI： 10.1016/j.jccase.2023.05.010

PubMed

researchmap
肺NTM症病態好酸球性気管支拡張症の増悪因子の検討

福田信彦, 村岡傑, 金子恵, 金子彩美, 染川弘平, 井澤亜美, 松本大海, 神巻千聡, 田中克志, 室橋光太, 藤井裕明, 青木絢子, 田上陽一, 渡邉恵介, 堀田信之, 原悠, 小林信明, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 156 - 156 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
当院における重症喘息に対するバイオ製剤サイクリングの現状

三竹捺央, 原悠, 藤井裕明, 井澤亜美, 金子恵, 村岡傑, 神巻千聡, 田中克志, 室橋光太, 田上陽一, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 391 - 391 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
びまん性肺疾患急性増悪線維性間質性肺疾患急性増悪における予後および線維化予測モデル構築の試み

田上陽一, 原悠, 金子恵, 村岡傑, 井澤亜美, 神巻千聡, 田中克志, 室橋光太, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 奥寺康司, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 177 - 177 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
膠原病を合併した気管支喘息症例の検討

渡邉恵介, 村岡傑, 金子恵, 染川弘平, 井澤亜美, 神巻千聡, 田中克志, 室橋光太, 田上陽一, 青木絢子, 堀田信之, 原悠, 小林信明, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 261 - 261 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis. 国際誌

Hiromi Matsumoto, Kohei Somekawa, Nobuyuki Horita, Suguru Ueda, Megumi Kaneko, Ayami Kaneko, Nobuhiko Fukuda, Ami Izawa, Chisato Kamimaki, Katsushi Tanaka, Kota Murohashi, Hiroaki Fuji, Yoichi Tagami, Ayako Aoki, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko

Therapeutic advances in medical oncology 15 17588359231198453 - 17588359231198453 2023年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic outcomes among cancer patients. Durvalumab plus tremelimumab (DT) is under investigation as a new ICI combination therapy, and its efficacy has been reported in various types of cancer. However, the safety profile of DT remains unclear, especially considering rare adverse events (AEs). OBJECTIVE: We aimed to assess the frequency of AEs associated with DT. DESIGN: This study type is a systematic review and meta-analysis. DATA SOURCES AND METHODS: Four databases were searched for articles. Randomized trials, single-arm trials, and prospective and retrospective observational studies were included. The type of cancer, previous treatment, and performance status were not questioned. Major AE indicators such as any AE and the pooled frequency of each specific AE were used as outcomes. As a subgroup analysis, we also compared cases in which DT was performed as first-line treatment with those in which it was performed as second-line or later treatment. The protocol for this systematic review was registered on the University Hospital Medical Information Network (UMIN) Center website (ID: UMIN000046751). RESULTS: Forty-one populations including 3099 patients were selected from 30 articles. Pooled frequencies of key AE indicators are shown below: any AEs, 77.8% [95% confidence interval (CI): 67.9-87.6]; grade ⩾ 3 AEs, 29.3% (95% CI: 24.2-34.4); serious AEs, 34.9% (95% CI: 28.1-41.7); AE leading to discontinuation, 13.3% (95% CI: 9.3-17.4); treatment-related deaths, 0.98% (95% CI: 0.5-1.5). AEs with a frequency exceeding 15% are shown below: fatigue, 30.1% (95% CI: 23.8-36.3); diarrhea, 21.7% (95% CI: 17.8-25.6); pruritus 17.9% (95% CI: 14.4-21.3); decreased appetite, 17.7% (95% CI: 13.7-22.0); nausea, 15.6% (95% CI: 12.1-19.6). There were no significant differences in these pooled frequencies between subgroups. CONCLUSIONS: The incidence of any AE in DT therapy was approximately 78%, and the incidence of grade 3 or higher AEs was approximately 30%, which was independent of prior therapy.

DOI： 10.1177/17588359231198453

PubMed

researchmap
The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study. 国際誌

Ayako Aoki, Yu Hara, Hiroaki Fujii, Kota Murohashi, Ryo Nagasawa, Yoichi Tagami, Tatsuji Enomoto, Yutaka Matsumoto, Makoto Masuda, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Makoto Kudo, Takashi Ogura, Takeshi Kaneko

PloS one 18 ( 9 ) e0291489 2023年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Among patients with idiopathic pulmonary fibrosis (IPF), few studies have investigated the clinical impact of anti-fibrotic treatment (AFT) with and without comorbidities. The aim of the study was to determine whether Charlson Comorbidity Index score (CCIS) can predict the efficacy of AFT in patients with IPF. METHODS: We retrospectively assessed data extracted from the medical records of IPF patients who received anti-fibrotic agents between 2009 and 2019. The collected data included age, sex, CCIS, pulmonary function test, high-resolution computed tomography (HRCT) pattern, gender/age/physiology (GAP) score, and 3-year IPF-related events defined as the first acute exacerbation or death within 3 years after starting AFT. RESULTS: We assessed 130 patients (median age, 74 years) who received nintedanib (n = 70) or pirfenidone (n = 60). Median duration of AFT was 425 days. Patients were categorized into high (≥ 3 points) and low (≤ 2 points) CCIS groups. There was no significant difference between the groups in terms of age, sex, duration of AFT, GAP score, or incidence of usual interstitial pneumonia pattern on HRCT except percentage predicted diffusion capacity of lung for carbon monoxide. Also, significant difference was not seen between the groups for 3-year IPF-related events (P = 0.75). Especially, in the low CCIS group but not the high CCIS group, the longer duration of AFT had better disease outcome. CONCLUSION: In the present study, we could not show any relation between CCIS and IPF disease outcomes in patients undergoing AFT, though the longer duration of AFT might be beneficial for IPF outcomes among patients with low CCIS.

DOI： 10.1371/journal.pone.0291489

PubMed

researchmap
ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease. 国際誌

Hiroaki Fujii, Yu Hara, Yusuke Saigusa, Yoichi Tagami, Kota Murohashi, Ryo Nagasawa, Ayako Aoki, Ami Izawa, Kenichi Seki, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko

Canadian respiratory journal 2023 5088207 - 5088207 2023年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The ILD-GAP scoring system has been widely used to predict the prognosis of patients with interstitial lung disease (ILD). The ability of the ILD-GAP scoring system combined with the Charlson Comorbidity Index score (CCIS) (ILD-GAPC) to predict ILD prognosis was investigated. METHODS: In ILD patients, including idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (iNSIP), collagen vascular disease-related interstitial pneumonia (CVD-IP), chronic hypersensitivity pneumonitis (CHP), and unclassifiable ILD (UC-ILD), treated between April 2013 and April 2017, the relationships between baseline clinical parameters, including age, sex, CCIS, ILD diagnosis, pulmonary function test results, and disease outcomes, were retrospectively assessed, and the ability to predict prognosis was compared between the ILD-GAP and ILD-GAPC models, respectively. RESULTS: A total of 185 patients (mean age, 71.9 years), all of whom underwent pulmonary function testing, including percentage predicted diffusion capacity for carbon monoxide, were assessed. ILD diagnosis consisted of IPF in 57 cases, iNSIP and CVD-IP in 117 cases, CHP in 6 cases, and UC-ILD in 5 cases. The ILD-GAPC provided a greater area under the receiver operating characteristic curve (0.758) for predicting 3-year ILD-related events than the ILD-GAP (0.721). In addition, log-rank tests showed that the Kaplan-Meier curves differed significantly among low, middle, and high ILD-GAPC scores (P < 0.001), unlike ILD-GAP scores (P = 0.083). CONCLUSIONS: The ILD-GAPC model could provide more accurate information for predicting prognosis in patients with ILD than the ILD-GAP model.

DOI： 10.1155/2023/5088207

PubMed

researchmap
DOCK2 is involved in the host genetics and biology of severe COVID-19. 国際誌

Ho Namkoong, Ryuya Edahiro, Tomomi Takano, Hiroshi Nishihara, Yuya Shirai, Kyuto Sonehara, Hiromu Tanaka, Shuhei Azekawa, Yohei Mikami, Ho Lee, Takanori Hasegawa, Koji Okudela, Daisuke Okuzaki, Daisuke Motooka, Masahiro Kanai, Tatsuhiko Naito, Kenichi Yamamoto, Qingbo S Wang, Ryunosuke Saiki, Rino Ishihara, Yuta Matsubara, Junko Hamamoto, Hiroyuki Hayashi, Yukihiro Yoshimura, Natsuo Tachikawa, Emmy Yanagita, Takayoshi Hyugaji, Eigo Shimizu, Kotoe Katayama, Yasuhiro Kato, Takayoshi Morita, Kazuhisa Takahashi, Norihiro Harada, Toshio Naito, Makoto Hiki, Yasushi Matsushita, Haruhi Takagi, Ryousuke Aoki, Ai Nakamura, Sonoko Harada, Hitoshi Sasano, Hiroki Kabata, Katsunori Masaki, Hirofumi Kamata, Shinnosuke Ikemura, Shotaro Chubachi, Satoshi Okamori, Hideki Terai, Atsuho Morita, Takanori Asakura, Junichi Sasaki, Hiroshi Morisaki, Yoshifumi Uwamino, Kosaku Nanki, Sho Uchida, Shunsuke Uno, Tomoyasu Nishimura, Takashi Ishiguro, Taisuke Isono, Shun Shibata, Yuma Matsui, Chiaki Hosoda, Kenji Takano, Takashi Nishida, Yoichi Kobayashi, Yotaro Takaku, Noboru Takayanagi, Soichiro Ueda, Ai Tada, Masayoshi Miyawaki, Masaomi Yamamoto, Eriko Yoshida, Reina Hayashi, Tomoki Nagasaka, Sawako Arai, Yutaro Kaneko, Kana Sasaki, Etsuko Tagaya, Masatoshi Kawana, Ken Arimura, Kunihiko Takahashi, Tatsuhiko Anzai, Satoshi Ito, Akifumi Endo, Yuji Uchimura, Yasunari Miyazaki, Takayuki Honda, Tomoya Tateishi, Shuji Tohda, Naoya Ichimura, Kazunari Sonobe, Chihiro Tani Sassa, Jun Nakajima, Yasushi Nakano, Yukiko Nakajima, Ryusuke Anan, Ryosuke Arai, Yuko Kurihara, Yuko Harada, Kazumi Nishio, Tetsuya Ueda, Masanori Azuma, Ryuichi Saito, Toshikatsu Sado, Yoshimune Miyazaki, Ryuichi Sato, Yuki Haruta, Tadao Nagasaki, Yoshinori Yasui, Yoshinori Hasegawa, Yoshikazu Mutoh, Tomoki Kimura, Tomonori Sato, Reoto Takei, Satoshi Hagimoto, Yoichiro Noguchi, Yasuhiko Yamano, Hajime Sasano, Sho Ota, Yasushi Nakamori, Kazuhisa Yoshiya, Fukuki Saito, Tomoyuki Yoshihara, Daiki Wada, Hiromu Iwamura, Syuji Kanayama, Shuhei Maruyama, Takashi Yoshiyama, Ken Ohta, Hiroyuki Kokuto, Hideo Ogata, Yoshiaki Tanaka, Kenichi Arakawa, Masafumi Shimoda, Takeshi Osawa, Hiroki Tateno, Isano Hase, Shuichi Yoshida, Shoji Suzuki, Miki Kawada, Hirohisa Horinouchi, Fumitake Saito, Keiko Mitamura, Masao Hagihara, Junichi Ochi, Tomoyuki Uchida, Rie Baba, Daisuke Arai, Takayuki Ogura, Hidenori Takahashi, Shigehiro Hagiwara, Genta Nagao, Shunichiro Konishi, Ichiro Nakachi, Koji Murakami, Mitsuhiro Yamada, Hisatoshi Sugiura, Hirohito Sano, Shuichiro Matsumoto, Nozomu Kimura, Yoshinao Ono, Hiroaki Baba, Yusuke Suzuki, Sohei Nakayama, Keita Masuzawa, Shinichi Namba, Ken Suzuki, Yoko Naito, Yu-Chen Liu, Ayako Takuwa, Fuminori Sugihara, James B Wing, Shuhei Sakakibara, Nobuyuki Hizawa, Takayuki Shiroyama, Satoru Miyawaki, Yusuke Kawamura, Akiyoshi Nakayama, Hirotaka Matsuo, Yuichi Maeda, Takuro Nii, Yoshimi Noda, Takayuki Niitsu, Yuichi Adachi, Takatoshi Enomoto, Saori Amiya, Reina Hara, Yuta Yamaguchi, Teruaki Murakami, Tomoki Kuge, Kinnosuke Matsumoto, Yuji Yamamoto, Makoto Yamamoto, Midori Yoneda, Toshihiro Kishikawa, Shuhei Yamada, Shuhei Kawabata, Noriyuki Kijima, Masatoshi Takagaki, Noah Sasa, Yuya Ueno, Motoyuki Suzuki, Norihiko Takemoto, Hirotaka Eguchi, Takahito Fukusumi, Takao Imai, Munehisa Fukushima, Haruhiko Kishima, Hidenori Inohara, Kazunori Tomono, Kazuto Kato, Meiko Takahashi, Fumihiko Matsuda, Haruhiko Hirata, Yoshito Takeda, Hidefumi Koh, Tadashi Manabe, Yohei Funatsu, Fumimaro Ito, Takahiro Fukui, Keisuke Shinozuka, Sumiko Kohashi, Masatoshi Miyazaki, Tomohisa Shoko, Mitsuaki Kojima, Tomohiro Adachi, Motonao Ishikawa, Kenichiro Takahashi, Takashi Inoue, Toshiyuki Hirano, Keigo Kobayashi, Hatsuyo Takaoka, Kazuyoshi Watanabe, Naoki Miyazawa, Yasuhiro Kimura, Reiko Sado, Hideyasu Sugimoto, Akane Kamiya, Naota Kuwahara, Akiko Fujiwara, Tomohiro Matsunaga, Yoko Sato, Takenori Okada, Yoshihiro Hirai, Hidetoshi Kawashima, Atsuya Narita, Kazuki Niwa, Yoshiyuki Sekikawa, Koichi Nishi, Masaru Nishitsuji, Mayuko Tani, Junya Suzuki, Hiroki Nakatsumi, Takashi Ogura, Hideya Kitamura, Eri Hagiwara, Kota Murohashi, Hiroko Okabayashi, Takao Mochimaru, Shigenari Nukaga, Ryosuke Satomi, Yoshitaka Oyamada, Nobuaki Mori, Tomoya Baba, Yasutaka Fukui, Mitsuru Odate, Shuko Mashimo, Yasushi Makino, Kazuma Yagi, Mizuha Hashiguchi, Junko Kagyo, Tetsuya Shiomi, Satoshi Fuke, Hiroshi Saito, Tomoya Tsuchida, Shigeki Fujitani, Mumon Takita, Daiki Morikawa, Toru Yoshida, Takehiro Izumo, Minoru Inomata, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Akihiro Ito, Yoshihiko Nakamura, Kota Hoshino, Junichi Maruyama, Hiroyasu Ishikura, Tohru Takata, Toshio Odani, Masaru Amishima, Takeshi Hattori, Yasuo Shichinohe, Takashi Kagaya, Toshiyuki Kita, Kazuhide Ohta, Satoru Sakagami, Kiyoshi Koshida, Kentaro Hayashi, Tetsuo Shimizu, Yutaka Kozu, Hisato Hiranuma, Yasuhiro Gon, Namiki Izumi, Kaoru Nagata, Ken Ueda, Reiko Taki, Satoko Hanada, Kodai Kawamura, Kazuya Ichikado, Kenta Nishiyama, Hiroyuki Muranaka, Kazunori Nakamura, Naozumi Hashimoto, Keiko Wakahara, Koji Sakamoto, Norihito Omote, Akira Ando, Nobuhiro Kodama, Yasunari Kaneyama, Shunsuke Maeda, Takashige Kuraki, Takemasa Matsumoto, Koutaro Yokote, Taka-Aki Nakada, Ryuzo Abe, Taku Oshima, Tadanaga Shimada, Masahiro Harada, Takeshi Takahashi, Hiroshi Ono, Toshihiro Sakurai, Takayuki Shibusawa, Yoshifumi Kimizuka, Akihiko Kawana, Tomoya Sano, Chie Watanabe, Ryohei Suematsu, Hisako Sageshima, Ayumi Yoshifuji, Kazuto Ito, Saeko Takahashi, Kota Ishioka, Morio Nakamura, Makoto Masuda, Aya Wakabayashi, Hiroki Watanabe, Suguru Ueda, Masanori Nishikawa, Yusuke Chihara, Mayumi Takeuchi, Keisuke Onoi, Jun Shinozuka, Atsushi Sueyoshi, Yoji Nagasaki, Masaki Okamoto, Sayoko Ishihara, Masatoshi Shimo, Yoshihisa Tokunaga, Yu Kusaka, Takehiko Ohba, Susumu Isogai, Aki Ogawa, Takuya Inoue, Satoru Fukuyama, Yoshihiro Eriguchi, Akiko Yonekawa, Keiko Kan-O, Koichiro Matsumoto, Kensuke Kanaoka, Shoichi Ihara, Kiyoshi Komuta, Yoshiaki Inoue, Shigeru Chiba, Kunihiro Yamagata, Yuji Hiramatsu, Hirayasu Kai, Koichiro Asano, Tsuyoshi Oguma, Yoko Ito, Satoru Hashimoto, Masaki Yamasaki, Yu Kasamatsu, Yuko Komase, Naoya Hida, Takahiro Tsuburai, Baku Oyama, Minoru Takada, Hidenori Kanda, Yuichiro Kitagawa, Tetsuya Fukuta, Takahito Miyake, Shozo Yoshida, Shinji Ogura, Shinji Abe, Yuta Kono, Yuki Togashi, Hiroyuki Takoi, Ryota Kikuchi, Shinichi Ogawa, Tomouki Ogata, Shoichiro Ishihara, Arihiko Kanehiro, Shinji Ozaki, Yasuko Fuchimoto, Sae Wada, Nobukazu Fujimoto, Kei Nishiyama, Mariko Terashima, Satoru Beppu, Kosuke Yoshida, Osamu Narumoto, Hideaki Nagai, Nobuharu Ooshima, Mitsuru Motegi, Akira Umeda, Kazuya Miyagawa, Hisato Shimada, Mayu Endo, Yoshiyuki Ohira, Masafumi Watanabe, Sumito Inoue, Akira Igarashi, Masamichi Sato, Hironori Sagara, Akihiko Tanaka, Shin Ohta, Tomoyuki Kimura, Yoko Shibata, Yoshinori Tanino, Takefumi Nikaido, Hiroyuki Minemura, Yuki Sato, Yuichiro Yamada, Takuya Hashino, Masato Shinoki, Hajime Iwagoe, Hiroshi Takahashi, Kazuhiko Fujii, Hiroto Kishi, Masayuki Kanai, Tomonori Imamura, Tatsuya Yamashita, Masakiyo Yatomi, Toshitaka Maeno, Shinichi Hayashi, Mai Takahashi, Mizuki Kuramochi, Isamu Kamimaki, Yoshiteru Tominaga, Tomoo Ishii, Mitsuyoshi Utsugi, Akihiro Ono, Toru Tanaka, Takeru Kashiwada, Kazue Fujita, Yoshinobu Saito, Masahiro Seike, Hiroko Watanabe, Hiroto Matsuse, Norio Kodaka, Chihiro Nakano, Takeshi Oshio, Takatomo Hirouchi, Shohei Makino, Moritoki Egi, Yosuke Omae, Yasuhito Nannya, Takafumi Ueno, Kazuhiko Katayama, Masumi Ai, Yoshinori Fukui, Atsushi Kumanogoh, Toshiro Sato, Naoki Hasegawa, Katsushi Tokunaga, Makoto Ishii, Ryuji Koike, Yuko Kitagawa, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, Yukinori Okada

Nature 609 ( 7928 ) 754 - 760 2022年9月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Identifying the host genetic factors underlying severe COVID-19 is an emerging challenge1-5. Here we conducted a genome-wide association study (GWAS) involving 2,393 cases of COVID-19 in a cohort of Japanese individuals collected during the initial waves of the pandemic, with 3,289 unaffected controls. We identified a variant on chromosome 5 at 5q35 (rs60200309-A), close to the dedicator of cytokinesis 2 gene (DOCK2), which was associated with severe COVID-19 in patients less than 65 years of age. This risk allele was prevalent in East Asian individuals but rare in Europeans, highlighting the value of genome-wide association studies in non-European populations. RNA-sequencing analysis of 473 bulk peripheral blood samples identified decreased expression of DOCK2 associated with the risk allele in these younger patients. DOCK2 expression was suppressed in patients with severe cases of COVID-19. Single-cell RNA-sequencing analysis (n = 61 individuals) identified cell-type-specific downregulation of DOCK2 and a COVID-19-specific decreasing effect of the risk allele on DOCK2 expression in non-classical monocytes. Immunohistochemistry of lung specimens from patients with severe COVID-19 pneumonia showed suppressed DOCK2 expression. Moreover, inhibition of DOCK2 function with CPYPP increased the severity of pneumonia in a Syrian hamster model of SARS-CoV-2 infection, characterized by weight loss, lung oedema, enhanced viral loads, impaired macrophage recruitment and dysregulated type I interferon responses. We conclude that DOCK2 has an important role in the host immune response to SARS-CoV-2 infection and the development of severe COVID-19, and could be further explored as a potential biomarker and/or therapeutic target.

DOI： 10.1038/s41586-022-05163-5

PubMed

researchmap
抗癌剤治療中に開放性結核を発症した症例の検討

須藤いい那, 神巻千聡, 小林信明, 金子恵, 村岡傑, 田中克志, 田上陽一, 室橋光太, 青木絢子, 渡邊恵介, 堀田信之, 原悠, 金子猛

日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 182回・251回 24 - 24 2022年9月

　詳細を見る

記述言語：日本語出版者・発行元：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会

researchmap
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. 国際誌

Qingbo S Wang, Ryuya Edahiro, Ho Namkoong, Takanori Hasegawa, Yuya Shirai, Kyuto Sonehara, Hiromu Tanaka, Ho Lee, Ryunosuke Saiki, Takayoshi Hyugaji, Eigo Shimizu, Kotoe Katayama, Masahiro Kanai, Tatsuhiko Naito, Noah Sasa, Kenichi Yamamoto, Yasuhiro Kato, Takayoshi Morita, Kazuhisa Takahashi, Norihiro Harada, Toshio Naito, Makoto Hiki, Yasushi Matsushita, Haruhi Takagi, Masako Ichikawa, Ai Nakamura, Sonoko Harada, Yuuki Sandhu, Hiroki Kabata, Katsunori Masaki, Hirofumi Kamata, Shinnosuke Ikemura, Shotaro Chubachi, Satoshi Okamori, Hideki Terai, Atsuho Morita, Takanori Asakura, Junichi Sasaki, Hiroshi Morisaki, Yoshifumi Uwamino, Kosaku Nanki, Sho Uchida, Shunsuke Uno, Tomoyasu Nishimura, Takashri Ishiguro, Taisuke Isono, Shun Shibata, Yuma Matsui, Chiaki Hosoda, Kenji Takano, Takashi Nishida, Yoichi Kobayashi, Yotaro Takaku, Noboru Takayanagi, Soichiro Ueda, Ai Tada, Masayoshi Miyawaki, Masaomi Yamamoto, Eriko Yoshida, Reina Hayashi, Tomoki Nagasaka, Sawako Arai, Yutaro Kaneko, Kana Sasaki, Etsuko Tagaya, Masatoshi Kawana, Ken Arimura, Kunihiko Takahashi, Tatsuhiko Anzai, Satoshi Ito, Akifumi Endo, Yuji Uchimura, Yasunari Miyazaki, Takayuki Honda, Tomoya Tateishi, Shuji Tohda, Naoya Ichimura, Kazunari Sonobe, Chihiro Tani Sassa, Jun Nakajima, Yasushi Nakano, Yukiko Nakajima, Ryusuke Anan, Ryosuke Arai, Yuko Kurihara, Yuko Harada, Kazumi Nishio, Tetsuya Ueda, Masanori Azuma, Ryuichi Saito, Toshikatsu Sado, Yoshimune Miyazaki, Ryuichi Sato, Yuki Haruta, Tadao Nagasaki, Yoshinori Yasui, Yoshinori Hasegawa, Yoshikazu Mutoh, Tomoki Kimura, Tomonori Sato, Reoto Takei, Satoshi Hagimoto, Yoichiro Noguchi, Yasuhiko Yamano, Hajime Sasano, Sho Ota, Yasushi Nakamori, Kazuhisa Yoshiya, Fukuki Saito, Tomoyuki Yoshihara, Daiki Wada, Hiromu Iwamura, Syuji Kanayama, Shuhei Maruyama, Takashi Yoshiyama, Ken Ohta, Hiroyuki Kokuto, Hideo Ogata, Yoshiaki Tanaka, Kenichi Arakawa, Masafumi Shimoda, Takeshi Osawa, Hiroki Tateno, Isano Hase, Shuichi Yoshida, Shoji Suzuki, Miki Kawada, Hirohisa Horinouchi, Fumitake Saito, Keiko Mitamura, Masao Hagihara, Junichi Ochi, Tomoyuki Uchida, Rie Baba, Daisuke Arai, Takayuki Ogura, Hidenori Takahashi, Shigehiro Hagiwara, Genta Nagao, Shunichiro Konishi, Ichiro Nakachi, Koji Murakami, Mitsuhiro Yamada, Hisatoshi Sugiura, Hirohito Sano, Shuichiro Matsumoto, Nozomu Kimura, Yoshinao Ono, Hiroaki Baba, Yusuke Suzuki, Sohei Nakayama, Keita Masuzawa, Shinichi Namba, Takayuki Shiroyama, Yoshimi Noda, Takayuki Niitsu, Yuichi Adachi, Takatoshi Enomoto, Saori Amiya, Reina Hara, Yuta Yamaguchi, Teruaki Murakami, Tomoki Kuge, Kinnosuke Matsumoto, Yuji Yamamoto, Makoto Yamamoto, Midori Yoneda, Kazunori Tomono, Kazuto Kato, Haruhiko Hirata, Yoshito Takeda, Hidefumi Koh, Tadashi Manabe, Yohei Funatsu, Fumimaro Ito, Takahiro Fukui, Keisuke Shinozuka, Sumiko Kohashi, Masatoshi Miyazaki, Tomohisa Shoko, Mitsuaki Kojima, Tomohiro Adachi, Motonao Ishikawa, Kenichiro Takahashi, Takashi Inoue, Toshiyuki Hirano, Keigo Kobayashi, Hatsuyo Takaoka, Kazuyoshi Watanabe, Naoki Miyazawa, Yasuhiro Kimura, Reiko Sado, Hideyasu Sugimoto, Akane Kamiya, Naota Kuwahara, Akiko Fujiwara, Tomohiro Matsunaga, Yoko Sato, Takenori Okada, Yoshihiro Hirai, Hidetoshi Kawashima, Atsuya Narita, Kazuki Niwa, Yoshiyuki Sekikawa, Koichi Nishi, Masaru Nishitsuji, Mayuko Tani, Junya Suzuki, Hiroki Nakatsumi, Takashi Ogura, Hideya Kitamura, Eri Hagiwara, Kota Murohashi, Hiroko Okabayashi, Takao Mochimaru, Shigenari Nukaga, Ryosuke Satomi, Yoshitaka Oyamada, Nobuaki Mori, Tomoya Baba, Yasutaka Fukui, Mitsuru Odate, Shuko Mashimo, Yasushi Makino, Kazuma Yagi, Mizuha Hashiguchi, Junko Kagyo, Tetsuya Shiomi, Satoshi Fuke, Hiroshi Saito, Tomoya Tsuchida, Shigeki Fujitani, Mumon Takita, Daiki Morikawa, Toru Yoshida, Takehiro Izumo, Minoru Inomata, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Akihiro Ito, Yoshihiko Nakamura, Kota Hoshino, Junichi Maruyama, Hiroyasu Ishikura, Tohru Takata, Toshio Odani, Masaru Amishima, Takeshi Hattori, Yasuo Shichinohe, Takashi Kagaya, Toshiyuki Kita, Kazuhide Ohta, Satoru Sakagami, Kiyoshi Koshida, Kentaro Hayashi, Tetsuo Shimizu, Yutaka Kozu, Hisato Hiranuma, Yasuhiro Gon, Namiki Izumi, Kaoru Nagata, Ken Ueda, Reiko Taki, Satoko Hanada, Kodai Kawamura, Kazuya Ichikado, Kenta Nishiyama, Hiroyuki Muranaka, Kazunori Nakamura, Naozumi Hashimoto, Keiko Wakahara, Sakamoto Koji, Norihito Omote, Akira Ando, Nobuhiro Kodama, Yasunari Kaneyama, Shunsuke Maeda, Takashige Kuraki, Takemasa Matsumoto, Koutaro Yokote, Taka-Aki Nakada, Ryuzo Abe, Taku Oshima, Tadanaga Shimada, Masahiro Harada, Takeshi Takahashi, Hiroshi Ono, Toshihiro Sakurai, Takayuki Shibusawa, Yoshifumi Kimizuka, Akihiko Kawana, Tomoya Sano, Chie Watanabe, Ryohei Suematsu, Hisako Sageshima, Ayumi Yoshifuji, Kazuto Ito, Saeko Takahashi, Kota Ishioka, Morio Nakamura, Makoto Masuda, Aya Wakabayashi, Hiroki Watanabe, Suguru Ueda, Masanori Nishikawa, Yusuke Chihara, Mayumi Takeuchi, Keisuke Onoi, Jun Shinozuka, Atsushi Sueyoshi, Yoji Nagasaki, Masaki Okamoto, Sayoko Ishihara, Masatoshi Shimo, Yoshihisa Tokunaga, Yu Kusaka, Takehiko Ohba, Susumu Isogai, Aki Ogawa, Takuya Inoue, Satoru Fukuyama, Yoshihiro Eriguchi, Akiko Yonekawa, Keiko Kan-O, Koichiro Matsumoto, Kensuke Kanaoka, Shoichi Ihara, Kiyoshi Komuta, Yoshiaki Inoue, Shigeru Chiba, Kunihiro Yamagata, Yuji Hiramatsu, Hirayasu Kai, Koichiro Asano, Tsuyoshi Oguma, Yoko Ito, Satoru Hashimoto, Masaki Yamasaki, Yu Kasamatsu, Yuko Komase, Naoya Hida, Takahiro Tsuburai, Baku Oyama, Minoru Takada, Hidenori Kanda, Yuichiro Kitagawa, Tetsuya Fukuta, Takahito Miyake, Shozo Yoshida, Shinji Ogura, Shinji Abe, Yuta Kono, Yuki Togashi, Hiroyuki Takoi, Ryota Kikuchi, Shinichi Ogawa, Tomouki Ogata, Shoichiro Ishihara, Arihiko Kanehiro, Shinji Ozaki, Yasuko Fuchimoto, Sae Wada, Nobukazu Fujimoto, Kei Nishiyama, Mariko Terashima, Satoru Beppu, Kosuke Yoshida, Osamu Narumoto, Hideaki Nagai, Nobuharu Ooshima, Mitsuru Motegi, Akira Umeda, Kazuya Miyagawa, Hisato Shimada, Mayu Endo, Yoshiyuki Ohira, Masafumi Watanabe, Sumito Inoue, Akira Igarashi, Masamichi Sato, Hironori Sagara, Akihiko Tanaka, Shin Ohta, Tomoyuki Kimura, Yoko Shibata, Yoshinori Tanino, Takefumi Nikaido, Hiroyuki Minemura, Yuki Sato, Yuichiro Yamada, Takuya Hashino, Masato Shinoki, Hajime Iwagoe, Hiroshi Takahashi, Kazuhiko Fujii, Hiroto Kishi, Masayuki Kanai, Tomonori Imamura, Tatsuya Yamashita, Masakiyo Yatomi, Toshitaka Maeno, Shinichi Hayashi, Mai Takahashi, Mizuki Kuramochi, Isamu Kamimaki, Yoshiteru Tominaga, Tomoo Ishii, Mitsuyoshi Utsugi, Akihiro Ono, Toru Tanaka, Takeru Kashiwada, Kazue Fujita, Yoshinobu Saito, Masahiro Seike, Hiroko Watanabe, Hiroto Matsuse, Norio Kodaka, Chihiro Nakano, Takeshi Oshio, Takatomo Hirouchi, Shohei Makino, Moritoki Egi, Yosuke Omae, Yasuhito Nannya, Takafumi Ueno, Tomomi Takano, Kazuhiko Katayama, Masumi Ai, Atsushi Kumanogoh, Toshiro Sato, Naoki Hasegawa, Katsushi Tokunaga, Makoto Ishii, Ryuji Koike, Yuko Kitagawa, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, Yukinori Okada

Nature communications 13 ( 1 ) 4830 - 4830 2022年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on a thorough analysis of whole blood RNA-seq data from 465 genotyped samples from the Japan COVID-19 Task Force, including 359 severe and 106 non-severe COVID-19 cases. We discover 1169 putative causal expression quantitative trait loci (eQTLs) including 34 possible colocalizations with biobank fine-mapping results of hematopoietic traits in a Japanese population, 1549 putative causal splice QTLs (sQTLs; e.g. two independent sQTLs at TOR1AIP1), as well as biologically interpretable trans-eQTL examples (e.g., REST and STING1), all fine-mapped at single variant resolution. We perform differential gene expression analysis to elucidate 198 genes with increased expression in severe COVID-19 cases and enriched for innate immune-related functions. Finally, we evaluate the limited but non-zero effect of COVID-19 phenotype on eQTL discovery, and highlight the presence of COVID-19 severity-interaction eQTLs (ieQTLs; e.g., CLEC4C and MYBL2). Our study provides a comprehensive catalog of whole blood regulatory variants in Japanese, as well as a reference for transcriptional landscapes in response to COVID-19 infection.

DOI： 10.1038/s41467-022-32276-2

PubMed

researchmap
Assessment of diagnostic utility of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial pneumonias. 国際誌

Yuki Kata, Yu Hara, Yoichi Tagami, Aya Yabe, Kota Murohashi, Ryo Nagasawa, Kentaro Nakashima, Hiroaki Fujii, Yusuke Saigusa, Masafumi Shiida, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko

Scientific reports 12 ( 1 ) 12935 - 12935 2022年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

The present study aimed to evaluate whether serum heme oxygenase (HO)-1 could be a reliable blood biomarker for diagnosing acute exacerbations (AEs) of both idiopathic interstitial pneumonia (IIP) and secondary interstitial pneumonia (SIP). Serum HO-1 levels of newly diagnosed patients with IP were measured, and the relationships between serum HO-1 and other serum biomarkers and high-resolution CT scores, were evaluated. Blood samples were collected from 90 patients with IIP, including 32 having an AE, and 32 with SIP, including 9 having an AE. The patients having an AE had significantly higher HO-1 levels than those not having an AE (35.2 ng/mL vs. 16.4 ng/mL; p < 0.001). On receiver operating characteristics (ROC) curve analysis for serum HO-1 ability to detect an AE, the area under the ROC curve (AUC) was 0.87 in patients with IIPs and 0.86 in those with SIPs. Also, in patients with both IIPs and SIPs, the combination of the serum HO-1 level and the GGO score showed favorable AUCs (IIPs: 0.92, SIPs: 0.83), though HO-1-not-including model (combination of LDH and GGO) also showed acceptable AUCs. Serum HO-1 could be a clinically useful biomarker for the accurate diagnosis of patients with AEs.

DOI： 10.1038/s41598-022-17290-0

PubMed

researchmap
Successful Treatment of Chylothorax and Chylopericardium by Radiotherapy in Lung Cancer.

Ryota Shintani, Akimasa Sekine, Kota Murohashi, Ryota Otoshi, Takeo Kasuya, Tsuneyuki Oda, Tomohisa Baba, Shigeru Komatsu, Takashi Ogura, Yoshikazu Inoue

Internal medicine (Tokyo, Japan) 61 ( 13 ) 2039 - 2043 2022年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

A 58-year-old man was diagnosed with stage IVB lung adenocarcinoma in the right upper lobe and underwent systemic chemotherapy. Seven months after the diagnosis, large left pleural and pericardial effusion was detected. The patient developed both chylothorax and chylopericardium following superior vena cava (SVC) obstruction with mediastinal lymphadenopathy caused by lung carcinoma. Since conservative treatment of the chyle leakage was ineffective, we administered radiotherapy to treat the SVC obstruction and mediastinal lymphadenopathy. After radiotherapy, the chylothorax and chylopericardium gradually resolved, and no further chyle leaks were identified on follow-up computed tomography. This case indicates that radiotherapy can be used to ameliorate lung cancer-related chylothorax and chylopericardium.

DOI： 10.2169/internalmedicine.8293-21

PubMed

researchmap
特発性肺線維症患者における合併症と、抗線維化薬の治療期間と有効性との関連についての検討(アンコール演題)

青木絢子, 原悠, 室橋光太, 長澤遼, 井澤亜美, 金子彩美, 染川弘平, 藤井裕明, 関健一, 田上陽一, 渡邉恵介, 堀田信之, 小林信明, 工藤誠, 平居義裕, 榎本達治, 増田誠, 松本裕, 金子猛

日本呼吸器学会誌 11 ( 増刊 ) 167 - 167 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
特発性肺線維症における抗線維化薬の多施設での使用経験について

平田萌々, 原悠, 室橋光太, 藤井裕明, 長澤遼, 田上陽一, 青木絢子, 渡邉恵介, 堀田信之, 増田誠, 小林信明, 工藤誠, 平居義裕, 榎本達治, 松本裕, 金子猛

日本呼吸器学会誌 11 ( 増刊 ) 168 - 168 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
血清ヘムオキシゲナーゼ-1(HO-1)の間質性肺炎急性増悪における有用性の検討

片佑樹, 原悠, 田上陽一, 室橋光太, 長澤遼, 青木絢子, 藤井裕明, 渡邉恵介, 堀田信之, 小林信明, 松本裕, 金子猛

日本呼吸器学会誌 11 ( 増刊 ) 245 - 245 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
線維性間質性肺疾患急性増悪における血清ヘムオキシゲナーゼ-1(HO-1)の有用性の検討

田上陽一, 原悠, 室橋光太, 長澤遼, 青木絢子, 関健一, 藤井裕明, 渡邉恵介, 堀田信之, 小林信明, 奥寺康司, 金子猛

日本呼吸器学会誌 11 ( 増刊 ) 297 - 297 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
血清ヘムオキシゲナーゼ-1(HO-1)が病勢と連動したウイルス感染を契機とした間質性肺疾患急性増悪(AE-ILD)

田上陽一, 原悠, 長澤遼, 室橋光太, 青木絢子, 藤井裕明, 関健一, 渡邉恵介, 堀田信之, 小林信明, 奥寺康司, 金子猛

日本呼吸器学会誌 11 ( 増刊 ) 297 - 297 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患患者におけるCharlson Comorbidity Indexスコアを用いたILD-GAPスコアリングモデルの改良の試み

藤井裕明, 原悠, 田上陽一, 室橋光太, 長澤遼, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 11 ( 増刊 ) 267 - 267 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach. 国際誌

Yayoi Kimura, Yusuke Nakai, Jihye Shin, Miyui Hara, Yuriko Takeda, Sousuke Kubo, Sundararaj Stanleyraj Jeremiah, Yoko Ino, Tomoko Akiyama, Kayano Moriyama, Kazuya Sakai, Ryo Saji, Mototsugu Nishii, Hideya Kitamura, Kota Murohashi, Kouji Yamamoto, Takeshi Kaneko, Ichiro Takeuchi, Eri Hagiwara, Takashi Ogura, Hideki Hasegawa, Tomohiko Tamura, Takeharu Yamanaka, Akihide Ryo

Scientific reports 11 ( 1 ) 20638 - 20638 2021年10月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

The COVID-19 pandemic is an unprecedented threat to humanity that has provoked global health concerns. Since the etiopathogenesis of this illness is not fully characterized, the prognostic factors enabling treatment decisions have not been well documented. Accurately predicting the progression of the disease would aid in appropriate patient categorization and thus help determine the best treatment option. Here, we have introduced a proteomic approach utilizing data-independent acquisition mass spectrometry (DIA-MS) to identify the serum proteins that are closely associated with COVID-19 prognosis. Twenty-seven proteins were differentially expressed between severely ill COVID-19 patients with an adverse or favorable prognosis. Ingenuity Pathway Analysis revealed that 15 of the 27 proteins might be regulated by cytokine signaling relevant to interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF), and their differential expression was implicated in the systemic inflammatory response and in cardiovascular disorders. We further evaluated practical predictors of the clinical prognosis of severe COVID-19 patients. Subsequent ELISA assays revealed that CHI3L1 and IGFALS may serve as highly sensitive prognostic markers. Our findings can help formulate a diagnostic approach for accurately identifying COVID-19 patients with severe disease and for providing appropriate treatment based on their predicted prognosis.

DOI： 10.1038/s41598-021-98253-9

PubMed

researchmap
Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019. 国際誌

Takafumi Yamaya, Eri Hagiwara, Tomohisa Baba, Takaaki Kitayama, Kota Murohashi, Katsuyuki Higa, Yozo Sato, Ryota Otoshi, Erina Tabata, Ryota Shintani, Hiroko Okabayashi, Satoshi Ikeda, Takashi Niwa, Atsuhito Nakazawa, Tsuneyuki Oda, Ryo Okuda, Akimasa Sekine, Hideya Kitamura, Shigeru Komatsu, Takashi Ogura

Respiratory investigation 59 ( 5 ) 596 - 601 2021年9月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The serum Krebs von den Lungen-6 (KL-6) level is a predictive factor for acute respiratory distress syndrome (ARDS). The development of ARDS has been reported in patients with coronavirus disease 2019 (COVID-19). This study aimed to determine whether serum KL-6 levels are associated with mortality and severity in patients with COVID-19. METHODS: Among 361 Japanese patients with COVID-19 who were hospitalized at Kanagawa Cardiovascular and Respiratory Center between February 2020 and December 2020, 356 patients with data on serum KL-6 levels were enrolled and their medical records were retrospectively analyzed. RESULTS: A negative correlation was observed between KL-6 levels and the ratio of the arterial partial pressure of oxygen to the fraction of inspired oxygen on admission. The KL-6 levels on admission and the maximal KL-6 levels were higher in patients with severe disease (n = 60) than in those with nonsevere disease (n = 296). Furthermore, the maximal KL-6 levels were higher in nonsurvivors (n = 6) than in survivors (n = 350). In nonsurvivors, the KL-6 levels increased as the disease progressed. The optimal cutoff value of the maximal KL-6 level for discriminating between survivors and nonsurvivors was 684 U/mL, with a sensitivity of 83.3%, a specificity of 90.5%, and an area under the curve of 0.89. CONCLUSIONS: The serum KL-6 level was associated with disease severity. Patients with KL-6 levels ≥684 U/mL had a significantly poorer outcome than those with KL-6 levels <684 U/mL.

DOI： 10.1016/j.resinv.2021.04.002

PubMed

researchmap
Heme Oxygenase-1 in Patients With Interstitial Lung Disease: A Review of the Clinical Evidence. 国際誌

Yu Hara, Kentaro Nakashima, Ryo Nagasawa, Kota Murohashi, Yoichi Tagami, Ayako Aoki, Koji Okudela, Takeshi Kaneko

The American journal of the medical sciences 362 ( 2 ) 122 - 129 2021年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

The clinical course and rate of progression of interstitial lung disease (ILD) are extremely variable among patients. For the purpose of monitoring disease activity, ILD diagnosis, and predicting disease prognosis, there are various biomarkers, including symptoms, physiological, radiological, and pathological findings, and peripheral blood and bronchoalveolar lavage fluid results. Of these, blood biomarkers such as sialylated carbohydrate antigen, surfactant proteins-A and -D, CC-chemokine ligand 18, matrix metalloprotease-1 and -7, CA19-9, and CA125 have been previously proposed. In the future, heme oxygenase-1 (HO-1) may also become a candidate ILD biomarker; it is a 32-kDa heat shock protein converting heme to carbon monoxide, biliverdin/bilirubin, and free iron to play a role in the pulmonary cytoprotective reaction in response to various stimuli. Recent research suggests that HO-1 can increase in lung tissues of patients with ILD, reflecting anti-inflammatory M2 macrophage activation, and the measurement of HO-1 levels in peripheral blood can be useful for evaluating the severity of lung damage in ILD and for predicting subsequent fibrosis formation.

DOI： 10.1016/j.amjms.2021.02.009

PubMed

researchmap
Clinical characteristics of Japanese patients with moderate to severe COVID-19. 国際誌

Ryota Otoshi, Eri Hagiwara, Takaaki Kitayama, Takafumi Yamaya, Katsuyuki Higa, Kota Murohashi, Yozo Sato, Erina Tabata, Ryota Shintani, Hiroko Okabayashi, Satoshi Ikeda, Takashi Niwa, Atsuhito Nakazawa, Tsuneyuki Oda, Ryo Okuda, Akiamasa Sekine, Hideya Kitamura, Tomohisa Baba, Shigeru Komatsu, Takashi Ogura

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 27 ( 6 ) 895 - 901 2021年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient's characteristics whose disease progressed to severe status. METHODS: The medical records of all consecutive 300 Japanese patients hospitalized at our institution between February and November 2020 were retrospectively reviewed. The clinical characteristics were evaluated to compare between mild (no oxygen needed), moderate (oxygen needs of 1-4 L/min), and severe diseases (oxygen needs of 5 L/min or more). RESULTS: The median age was 68 years old, with 123 (41.0%) males and 177 (59.0%) females. Of these, 199 patients (66.3%), 55 patients (18.3%), 46 patients (15.3%) patients were in the mild disease, moderate disease, severe disease groups, respectively. Patients with severe disease were more likely to be older, have more comorbidities, and tended to have higher body mass index. In laboratory data, lymphocyte count, levels of C-reactive protein (CRP), LDH, and AST on admission were significantly associated with the severity. In multivariate analysis, age and CRP were the independent risk factors for severe disease (OR = 1.050, 1.130, respectively). The optimal cut-off value for age was 74 years old and that for CRP was 3.15 mg/dL. CONCLUSIONS: Age and CRP were independently associated with disease severity of COVID-19 in multivariate analysis. Additionally, the numbers of underlying disease, lymphocyte count, and inflammatory markers such as LDH and D-dimer may also be related to disease severity.

DOI： 10.1016/j.jiac.2021.02.028

PubMed

researchmap
間質性肺疾患急性増悪における予後予測因子としての血清HO-1 経時的変動と病理所見を含めた検討

田上陽一, 原悠, 室橋光太, 長澤遼, 青木絢子, 染川弘平, 福田信彦, 橋本恒, 堂下皓世, 田中克志, 中島健太郎, 渡邉恵介, 堀田信之, 奥寺康司, 小林信明, 金子猛

日本呼吸器学会誌 10 ( 増刊 ) 140 - 140 2021年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患における長期予後予測モデルの作成の試み(アンコール演題)

上田傑, 原悠, 室橋光太, 三枝祐輔, 柳生洋行, 長澤遼, 青木絢子, 陳昊, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛

日本呼吸器学会誌 10 ( 増刊 ) 128 - 128 2021年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
ステロイドパルス療法を要する間質性肺疾患急性増悪に対するマクロライド系抗菌薬の有用性について

長澤遼, 原悠, 室橋光太, 田上陽一, 青木絢子, 中島健太郎, 橋本恒, 堂下皓世, 渡邉恵介, 田中克志, 福田信彦, 染川弘平, 片倉誠悟, 増本菜美, 陳昊, 久保創介, 神巻千聡, 松本大海, 堀田信之, 小林信明, 工藤誠, 金子猛

日本呼吸器学会誌 10 ( 増刊 ) 224 - 224 2021年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
ARDSと間質性肺疾患の急性増悪の疾患活動性および予後評価における血清ヘムオキシゲナーゼ1の有用性について

長澤遼, 原悠, 室橋光太, 田上陽一, 青木絢子, 中島健太郎, 橋本恒, 堂下皓世, 渡邉恵介, 田中克志, 福田信彦, 染川弘平, 片倉誠悟, 増本菜美, 陳昊, 久保創介, 神巻千聡, 松本大海, 堀田信之, 小林信明, 工藤誠, 金子猛

日本呼吸器学会誌 10 ( 増刊 ) 264 - 264 2021年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患急性増悪におけるKL-6高値群と低値群の臨床像の違い

田上陽一, 原悠, 室橋光太, 長澤遼, 青木絢子, 染川弘平, 福田信彦, 橋本恒, 堂下皓世, 田中克志, 中島健太郎, 渡邉恵介, 堀田信之, 小林信明, 金子猛

日本呼吸器学会誌 10 ( 増刊 ) 140 - 140 2021年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
特発性間質性肺炎と二次性間質性肺炎の急性増悪の臨床像および予後予測因子の解析

西川裕里香, 原悠, 田上陽一, 室橋光太, 長澤遼, 青木絢子, 橋本恒, 堂下皓世, 田中克志, 中島健太郎, 渡邉恵介, 堀田信之, 小林信明, 山本昌樹, 工藤誠, 金子猛

日本呼吸器学会誌 10 ( 増刊 ) 217 - 217 2021年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases. 国際誌

Yoichi Tagami, Yu Hara, Kota Murohashi, Ryo Nagasawa, Yurika Nishikawa, Meiro Tanaka, Ayako Aoki, Katsushi Tanaka, Kentaro Nakashima, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Masaki Yamamoto, Makoto Kudo, Koji Okudela, Takeshi Kaneko

Canadian respiratory journal 2021 9099802 - 9099802 2021年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Serum Krebs von den Lungen-6 (KL-6) measurement is widely used to assess disease activity or prognosis in patients with interstitial lung diseases (ILDs). However, the clinical differences between high and low serum KL-6 levels at the time of acute exacerbation (AE) of ILD are not well known. METHODS: Clinical parameters including age, sex, Charlson Comorbidity Index score (CCIS), blood biomarkers, high-resolution CT findings, and disease mortality were retrospectively compared between high and low KL-6 (cutoff value: 1000 U/mL) patients at the time of diagnosis of AE of ILDs. RESULTS: Thirty-eight high serum KL-6 and 57 low serum KL-6 patients were included. There was no significant difference in 6-month mortality between them (P = 0.685), whereas serum lactate dehydrogenase was a significant predictor of 6-month mortality in the high serum KL-6 patients (odds ratio (OR): 1.006; 95% confidence interval (CI): 1.003-1.009; P < 0.001), and CCIS (OR: 1.502; 95% CI: 1.242-1.838; P < 0.001) and sex (OR: 5.751; 95% CI: 1.121-105.163; P = 0.033) were significant predictors in low serum KL-6 patients. In addition, the incidences of congestive heart failure, symptomatic chronic pulmonary disease, cerebrovascular disease, and second metastatic solid tumours were significantly higher in nonsurvivors with low serum KL-6 than in other groups (P < 0.05). CONCLUSIONS: The clinical features in patients with AEs of ILDs may differ depending on the serum KL-6 level, and clinicopathological examination according to this subtyping guided by the serum KL-6 level is essential.

DOI： 10.1155/2021/9099802

PubMed

researchmap
The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease. 国際誌

Yurika Nishikawa, Yu Hara, Yoichi Tagami, Ryo Nagasawa, Kota Murohashi, Ayako Aoki, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko

Canadian respiratory journal 2021 7456315 - 7456315 2021年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The purpose of this retrospective study was to clarify whether the presence of honeycombing on computed tomography (CT) can affect the prognosis of patients with acute exacerbations (AEs) of interstitial lung diseases (ILDs). METHODS: Clinical parameters including age, sex, Charlson Comorbidity Index Score (CCIS), blood biomarkers, and 3-month mortality were retrospectively compared between the CT honeycombing present and absent groups at the diagnosis of AEs of ILDs. RESULTS: Ninety-five patients who were on corticosteroid pulse therapy were assessed. Though log-rank tests showed that Kaplan-Meier survival curves of the high and low ground-glass opacity (GGO) score groups differed significantly in 3-month mortality in patients with AEs of idiopathic ILDs (P = 0.007) and overall patients (P = 0.045), there was no significant difference between the CT honeycombing present and absent groups in patients with AEs of idiopathic ILDs (P = 0.472) and AEs of secondary ILDs (P = 0.905), as well as of overall patients (P = 0.600). In addition, whereas CCIS (OR, 1.436; 95% CI, 1.156-1.842; P < 0.001) was a significant predictor of 3-month mortality in the CT honeycombing absent group, serum LDH (OR, 1.005; 95% CI, 1.002-1.007; P = 0.001) was a significant predictor in the CT honeycombing present group. CONCLUSIONS: The clinical features of patients with or without honeycombing may differ due to the difference in prognostic factors, but these groups were found to have similar prognoses 3 months after AE onset, and clinicopathological examinations according to these groups are essential.

DOI： 10.1155/2021/7456315

PubMed

researchmap
Serum heme oxygenase-1 measurement is useful for evaluating disease activity and outcomes in patients with acute respiratory distress syndrome and acute exacerbation of interstitial lung disease. 国際誌

Ryo Nagasawa, Yu Hara, Kota Murohashi, Ayako Aoki, Nobuaki Kobayashi, Shigeto Takagi, Satoru Hashimoto, Akihiko Kawana, Takeshi Kaneko

BMC pulmonary medicine 20 ( 1 ) 310 - 310 2020年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Oxidative stress plays an important role in acute lung injury, which is associated with the development and progression of acute respiratory failure. Here, we investigated whether the degree of oxidative stress as indicated by serum heme oxygenase-1 (HO-1) is clinically useful for predicting prognosis among the patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of interstitial lung disease (AE-ILD). METHODS: Serum HO-1 levels of newly diagnosed or untreated ARDS and AE-ILD patients were measured at diagnosis. Relationships between serum HO-1 and other clinical parameters and 1 and 3-month mortality were evaluated. RESULTS: Fifty-five patients including 22 of ARDS and 33 of AE-ILD were assessed. Serum HO-1 level at diagnosis was significantly higher in ARDS patients than AE-ILD patients (87.8 ± 60.0 ng/mL vs. 52.5 ± 36.3 ng/mL, P < 0.001). Serum HO-1 correlated with serum total bilirubin (R = 0.454, P < 0.001) and serum LDH (R = 0.500, P < 0.001). In both patients with ARDS and AE-ILDs, serum HO-1 level tended to decrease from diagnosis to 2 weeks after diagnosis, however, did not normalized. Composite parameters including serum HO-1, age, sex, and partial pressure of oxygen in arterial blood/fraction of inspired oxygen (P/F) ratio for prediction of 3-month mortality showed a higher AUC (ARDS: 0.925, AE-ILDs: 0.892) than did AUCs of a single predictor or combination of two or three predictors. CONCLUSION: Oxidative stress assessed by serum HO-1 is persistently high among enrolled patients for 2 weeks after diagnosis. Also, serum HO-1 levels at the diagnosis combined with age, sex, and P/F ratio could be clinically useful for predicting 3-month mortality in both ARDS and AE-ILD patients.

DOI： 10.1186/s12890-020-01341-1

PubMed

researchmap
Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors.

Takafumi Yamaya, Tomohisa Baba, Eri Hagiwara, Satoshi Ikeda, Takashi Niwa, Takaaki Kitayama, Kota Murohashi, Katsuyuki Higa, Yozo Sato, Takashi Ogura

Internal medicine (Tokyo, Japan) 59 ( 22 ) 2921 - 2925 2020年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Coronavirus disease 2019 (COVID-19) has been recognized as a worldwide pandemic. However, the clinical course of COVID-19 remains poorly characterized. Although some cases of pneumothorax have been reported, they all had pulmonary complications or were managed with mechanical ventilation. We herein report a case of pneumothorax that developed even though the patient had no pulmonary underlying diseases and had never been managed with mechanical ventilation. In the present case, a lung bulla was found on chest computed tomography during treatment for COVID-19. We concluded that COVID-19 affected the formation of the lung bulla and induced the complication of pneumothorax.

DOI： 10.2169/internalmedicine.5731-20

PubMed

researchmap
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. 国際誌

Kota Murohashi, Eri Hagiwara, Takaaki Kitayama, Takafumi Yamaya, Katsuyuki Higa, Yozo Sato, Ryota Otoshi, Ryota Shintani, Hiroko Okabayashi, Satoshi Ikeda, Takashi Niwa, Atsuhito Nakazawa, Tsuneyuki Oda, Ryo Okuda, Akimasa Sekine, Hideya Kitamura, Tomohisa Baba, Shigeru Komatsu, Tae Iwasawa, Takeshi Kaneko, Takashi Ogura

Respiratory investigation 58 ( 6 ) 430 - 434 2020年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Although the use of corticosteroids is not recommended in the World Health Organization statement for the treatment of coronavirus disease 2019 (COVID-19), steroid therapy may be indicated for critical cases in specific situations. Here, we report the successful treatment of 11 cases of severe COVID-19 pneumonia with favipiravir and methylprednisolone. All cases were severe and patients required oxygen administration or had a blood oxygen saturation ≤93% on room air. All were treated with favipiravir and methylprednisolone, and 10 of 11 patients responded well and required no further oxygen supplementation or ventilator management. This study shows the importance of the early-stage use of a combination of favipiravir and methylprednisolone in severe cases to achieve a favorable clinical outcome.

DOI： 10.1016/j.resinv.2020.08.001

PubMed

researchmap
Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease. 国際誌

Hiroyuki Yagyu, Kota Murohashi, Yu Hara, Yusuke Saigusa, Ayako Aoki, Nobuaki Kobayashi, Takeshi Kaneko

Journal of thoracic disease 12 ( 10 ) 5774 - 5782 2020年10月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Prognostic factors have yet to be established for patients with interstitial lung disease (ILD). We aimed to clarify whether the Charlson Comorbidity Index score (CCIS) could help predict disease prognosis in patients with ILD. METHODS: Among ILD patients treated between April 2013 and April 2017, we retrospectively assessed the relationship between baseline clinical parameters including age, sex, CCIS, ILD diagnosis, pulmonary function test results, and 3-year ILD-related events including cause-specific death and first acute exacerbation (AE). RESULTS: We assessed 180 patients (mean age, 74 years), all of whom underwent pulmonary function testing including percentage predicted diffusion capacity for carbon monoxide (%DLco). Underlying pathologies included idiopathic pulmonary fibrosis (IPF) in 57 cases, idiopathic nonspecific interstitial pneumonia (iNSIP) and collagen vascular disease-related interstitial pneumonia in 117 cases, and chronic hypersensitivity pneumonia (CHP) in 6 cases. A composite scoring system comprising IPF diagnosis, CCIS, and %DLco provided a favorable C-index (0.825) for predicting 3-year ILD-related events. The nomogram for 3-year prognosis revealed the largest contributions from CCIS, %DLco and IPF diagnosis. CONCLUSIONS: This composite scoring system accounting for IPF diagnosis, CCIS, and %DLco could provide a useful tool for predicting prognosis in relatively mild ILD patients tolerated to pulmonary diffusion capacity testing.

DOI： 10.21037/jtd-20-1302

PubMed

researchmap
Serum surfactant protein A as a surrogate biomarker of a negative heart sign among patients with interstitial lung disease.

Hisashi Sasaki, Yu Hara, Masataka Taguri, Yuji Fujikura, Kota Murohashi, Hiroyuki Yagyu, Takeshi Kaneko, Akihiko Kawana

Nagoya journal of medical science 82 ( 3 ) 499 - 508 2020年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

The mechanisms underlying interstitial lung disease (ILD) are characterized by variable inﬂammation or ﬁbrosis of the pulmonary interstitium. A negative heart sign (NHS) on 67Ga scintigrams of patients with ILD is due to considerably increased inflammatory activity in the lungs. We retrospectively analyzed relationships between NHS and established biomarkers of disease severity in patients with ILD. Among 81 consecutive non-smoking patients with ILD (mean age, 63 years) who had been hospitalized between April 2009 and October 2011, we selected 52 who had been assessed by 67Ga scintigraphy. We then evaluated relationships between NHS and blood biomarkers, pulmonary function and high-resolution computed tomography (HRCT). Among these 52 patients, 10 showed idiopathic pulmonary fibrosis and 42 had other ILD. Multivariate analysis with stepwise variable selection, serum surfactant protein (SP)-A (OR (odds ratio), 1.026; 95%CI (confidence interval), 1.003-1.050; P = 0.024) and inflammation index calculated from HRCT findings (OR, 1.358; 95%CI, 1.079-1.709; P = 0.009) were significant predictors of an NHS. Serum SP-A offered 85% sensitivity and 75% specificity for predicting NHS at an optimal cut-off of 45.8 ng/mL. Serum SP-A concentrations correlated positively with inflammation index (r = 0.344, P = 0.015). In conclusion, serum SP-A might serve as a surrogate biomarker for predicting an NHS in patients with ILD.

DOI： 10.18999/nagjms.82.3.499

PubMed

researchmap
間質性肺疾患における長期予後予測モデルの作成の試み

上田傑, 原悠, 室橋光太, 三枝祐輔, 柳生洋行, 長澤遼, 青木絢子, 陳昊, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 302 - 302 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患急性増悪における血清HO-1とチャールソン併存疾患指数(CCI)を組み合わせた予後予測モデルの有用性の検証

田上陽一, 原悠, 室橋光太, 青木絢子, 張田佳代, 陳昊, 長澤遼, 柳生洋行, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 199 - 199 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患急性増悪における血清D-dimerの臨床組織学的考察

長澤遼, 原悠, 室橋光太, 張田佳代, 松村雅仁, 川村飛翔, 柳生洋行, 青木絢子, 陳昊, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 工藤誠, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 252 - 252 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
肺癌トランスレーショナル EGFR遺伝子変異陽性肺癌の腫瘍オルガノイドの作成とEGFR-TKI耐性の検討

藤本拓也, 片倉誠悟, 小林信明, 橋本恒, 田中克志, 井上玲, 長澤遼, 池田美彩子, 室橋光太, 陳昊, 増本菜美, 青木絢子, 中島健太郎, 湯本健太郎, 寺西周平, 渡邊弘樹, 渡邉恵介, 原悠, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 133 - 133 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
特発性肺線維症(IPF)患者における抗線維化薬内服期間と長期予後との関連性の検討(多施設共同研究)

青木絢子, 原悠, 室橋光太, 陳昊, 長澤遼, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛, 工藤誠, 平馬暢之, 榎本達治

日本呼吸器学会誌 9 ( 増刊 ) 153 - 153 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
An autopsy case of ventilator-associated tracheobronchitis caused by Corynebacterium species complicated with diffuse alveolar damage. 国際誌

Ryo Nagasawa, Yu Hara, Takuya Miyazaki, Kota Murohashi, Hiroki Watanabe, Takeshi Kaneko

Respiratory medicine case reports 31 101208 - 101208 2020年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Ventilator-associated tracheobronchitis (VAT) has been reported to occur in 11% of intubated patients. Corynebacterium spp. can cause lower respiratory infections; however, to our knowledge, there have been no reported cases of VAT caused by Corynebacterium spp. A 55-year-old man was hospitalized with acute respiratory failure after autologous peripheral blood stem cell transplantation for Hodgkin lymphoma. Chest computed tomography showed diffuse ground-glass opacities in both lung fields. A few days after tracheal intubation, steroid pulse, and antibacterial drugs, the patient's pulmonary involvement temporarily improved. However, these opacities rapidly deteriorated, leading to death about 2 weeks after hospitalization. No significant bacteria other than Corynebacterium spp. were detected in sputum cultures during treatment and in blood culture at autopsy. Histological findings revealed tracheitis and diffuse alveolar damage. According to these findings, we diagnosed the patient as having VAT caused by Corynebacterium spp. This report suggests that Corynebacterium spp. might be an important causative pathogen of VAT in immunodeficient patients who undergo tracheal intubation. Additionally, optimal treatment for Corynebacterium spp. must be determined.

DOI： 10.1016/j.rmcr.2020.101208

PubMed

researchmap
Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies. 国際誌

Sousuke Kubo, Norihisa Ohtake, Kei Miyakawa, Sundararaj Stanleyraj Jeremiah, Yutaro Yamaoka, Kota Murohashi, Eri Hagiwara, Takahiro Mihara, Atsushi Goto, Etsuko Yamazaki, Takashi Ogura, Takeshi Kaneko, Takeharu Yamanaka, Akihide Ryo

Frontiers in microbiology 11 628281 - 628281 2020年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVES: Serological tests for COVID-19 have been instrumental in studying the epidemiology of the disease. However, the performance of the currently available tests is plagued by the problem of variability. We have developed a high-throughput serological test capable of simultaneously detecting total immunoglobulins (Ig) and immunoglobulin G (IgG) against nucleocapsid protein (NP) and spike protein (SP) and report its performance in detecting COVID-19 in clinical samples. METHODS: We designed and prepared reagents for measuring NP-IgG, NP-Total Ig, SP-IgG, and SP-Total Ig (using N-terminally truncated NP (ΔN-NP) or receptor-binding domain (RBD) antigen) dedicated automated chemiluminescent enzyme immunoassay analyzer AIA-CL1200. After determining the basal thresholds based on 17 sera obtained from confirmed COVID-19 patients and 600 negative sera, the clinical validity of the assay was evaluated using independent 202 positive samples and 1,000 negative samples from healthy donors. RESULTS: All of the four test parameters showed 100% specificity individually (1,000/1,000; 95%CI, 99.63-100). The sensitivity of the assay increased proportionally to the elapsed time from symptoms onset, and all the tests achieved 100% sensitivity (153/153; 95%CI, 97.63-100) after 13 days from symptoms onset. NP-Total Ig was the earliest to attain maximal sensitivity among the other antibodies tested. CONCLUSION: Our newly developed serological testing exhibited 100% sensitivity and specificity after 13 days from symptoms onset. Hence, it could be used as a reliable method for accurate detection of COVID-19 patients and to evaluate seroprevalence and possibly for surrogate assessment of herd immunity.

DOI： 10.3389/fmicb.2020.628281

PubMed

researchmap
Diffuse alveolar hemorrhage complicating acute exacerbation of IPF. 国際誌

Kota Murohashi, Yu Hara, Ayako Aoki, Masahito Matsumura, Toshiro Kataoka, Koji Okudela, Takeshi Kaneko

Respiratory medicine case reports 29 101022 - 101022 2020年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

An 83-year-old man with a history of interstitial lung disease (ILD) presented with a 1-week history of progressive dyspnea. Computed tomography of the chest revealed right lung-predominant, diffuse, ground glass opacities superimposed upon reticular opacities. Despite methylprednisolone pulse therapy under a diagnosis of acute exacerbation (AE) of ILD, lung involvement and renal dysfunction worsened and disseminated intravascular coagulation developed. The patient died on day 5 of hospitalization. Pathological examination at autopsy revealed diffuse alveolar hemorrhage (DAH) superimposed upon organizing diffuse alveolar damage and usual interstitial pneumonia. We reached a final diagnosis of DAH-predominant AE of idiopathic pulmonary fibrosis (IPF). Abundant expression of the oxidative stress marker hemeoxygenase-1 (HO-1) was observed in alveolar macrophages. These suggest that HO-1 expression in the lungs may offer a useful biomarker for this atypical histological subtype of AE of IPF.

DOI： 10.1016/j.rmcr.2020.101022

PubMed

researchmap
Giant Solitary Fibrous Tumor of Pleura Presenting Both Benign and Malignant Features. 国際誌

Hiroyuki Yagyu, Yu Hara, Kota Murohashi, Yoshihiro Ishikawa, Tetsuya Isaka, Tetsukan Woo, Takeshi Kaneko

The American journal of case reports 20 1755 - 1759 2019年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND The incidence of solitary fibrous tumor of the pleura (SFTP) is less than 5% of all pleural tumors. It is important to determine whether the tumor is benign or malignant in deciding on treatment and estimating prognosis, but this can sometimes be difficult. CASE REPORT A 59-year-old woman with no prior medical history presented with a 4-month history of right back pain and dyspnea. Contrast-enhanced computed tomography revealed a giant oval mass with inhomogeneous intensities, and bloody pleural effusion in the right thoracic cavity, proved to be solitary fibrous tumor of pleura (SFTP) under the complete thoracoscopic resection. The resected tumor seemed to have several malignant features, including large size of tumor, inhomogeneous intensities, and pleural effusion due to intratumor hemorrhage; however, Ki-67 (MIB-I) proliferation index was less than 1%, with no recurrence seen within 2 year after symptom onset. CONCLUSIONS We managed a case of SFTP presenting both malignant and benign features. In patients with SFTP, multi-disciplinary discussion among the clinician, radiologist, and pathologist was considered to be needed for estimating disease prognosis.

DOI： 10.12659/AJCR.919639

PubMed

researchmap
OP/NSIP overlapを認めた抗EJ、Ro-52抗体陽性間質性肺炎の1例

井上薫, 室橋光太, 原悠, 湯本健太郎, 寺西周平, 金子猛

日本呼吸器学会誌 8 ( 6 ) 410 - 414 2019年11月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

症例は60歳女性。数ヵ月前より持続する労作時呼吸困難にて受診した。胸部HRCTにて間質性肺炎を認めた。筋炎症状を含めた明らかな膠原病関連症状は認めなかったものの、血清抗EJ抗体および抗Ro-52抗体が陽性であった。外科的肺生検では、非特異性間質性肺炎と器質化肺炎が混在する所見を認めた。両抗体が陽性の症例は、筋炎やrapidly progressive-interstitial lung diseaseの合併を考慮すべき予後不良病態であることが予想され、厳重な経過観察が必要と考えられた。(著者抄録)

researchmap
Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. 国際誌

Kota Murohashi, Yu Hara, Yusuke Saigusa, Nobuaki Kobayashi, Takashi Sato, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko

Journal of thoracic disease 11 ( 6 ) 2448 - 2457 2019年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: A prognostic factor for patients with acute or subacute idiopathic interstitial pneumonias (IIPs) or acute exacerbation (AE) of collagen vascular diseases-related interstitial pneumonia (CVD-IP) has not been established. We aimed to determine whether the Charlson comorbidity index (CCI) could serve as a prognostic factor for patients with these patients. METHODS: We assessed baseline prognostic factors among patients with acute or subacute IIPs and AE of CVD-IP who were admitted to hospital between January 2014 and December 2017. We classified them as survivors and non-survivors at 3 months and compared their age, sex, CCI, blood parameters [lactate dehydrogenase (LDH), surfactant protein (SP)-D, Krebs von den Lungen-6, and partial pressure of oxygen in arterial blood/fraction of the inspiratory oxygen], high resolution CT (HRCT) scores and treatment. RESULTS: Sixty eight patients with (mean age, 75 years), were assessed. All patients received steroid pulse therapy. We found that 45 of acute or subacute IIPs and 16 of AE of CVD-IP were included. Stepwise multivariate analysis selected CCI (OR, 1.306; 95% CI, 1.090-1.573; P=0.004), serum LDH (OR, 1.003; 95% CI, 1.001-1.005; P=0.002), and sex (OR, 8.555; 95% CI, 1.729-154.978; P=0.038) as significant predictors of 3-month mortality among these patients. Three-month mortality was significantly worse among patients with high (≥4) than low (<4) CCI (mortality rates: 63.2% vs. 16.3%, P<0.001). Moreover, the composite scoring system including CCI, serum LDH, and sex was acceptable (Bootstrap AUC, 0.859; Bootstrap C-index, 0.747). CONCLUSIONS: The composite scoring system including CCI, sex, and serum LDH could be a useful mortality prediction tool for patients with acute or subacute IIPs and AE of CVD-IP requiring steroid pulse therapy.

DOI： 10.21037/jtd.2019.05.46

PubMed

researchmap
Clinical Significance of Serum Hemeoxygenase-1 as a New Biomarker for the Patients with Interstitial Pneumonia. 国際誌

Kota Murohashi, Yu Hara, Kanako Shinada, Kenjiro Nagai, Masaharu Shinkai, Akihiko Kawana, Takeshi Kaneko

Canadian respiratory journal 2018 7260178 - 7260178 2018年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Serum hemeoxygenase-1 (HO-1) has been proposed to be a biomarker of lung disease activity and prognosis. The present study aimed at evaluating whether HO-1 could be a useful marker for evaluating disease activity and predicting prognosis in patients with interstitial pneumonia (IP). MATERIALS AND METHODS: Serum HO-1 levels of newly diagnosed or untreated patients with IP were measured at hospitalization. We evaluated the relationships between serum HO-1 and other serum biomarkers, high resolution CT (HRCT) findings, and hospital mortality. RESULTS: Twenty-eight patients with IP, including 14 having an acute exacerbation (AE) and 14 not having an AE, were evaluated. The patients having an AE had significantly higher HO-1 levels than those not having an AE (53.5 ng/mL vs. 24.1 ng/mL; p < 0.001), and the best cut-off level to discriminate between having an AE or not having an AE was 41.6 ng/mL. Serum HO-1 levels were positively correlated with serum levels of surfactant protein-D (r=0.66, p < 0.001) and the ground glass opacity score (calculated from HRCT; r=0.40, p=0.036). Patients who subsequently died in hospital had presented with significantly higher HO-1 levels than those who did not die in hospital (64.8 ng/mL vs. 32.0 ng/mL; p=0.009). CONCLUSION: Serum HO-1 may serve as a useful biomarker for detecting AE or predicting hospital mortality in patients with IP.

DOI： 10.1155/2018/7260178

PubMed

researchmap
当院及び関連2病院における既治療進行非小細胞肺癌患者に対するNivolumabの使用経験

寺西周平, 小林信明, 篠田雅宏, 下川路伊亮, 新海正晴, 小泉晴美, 高橋健一, 室橋光太, 宮沢直幹, 工藤誠, 金子猛

日本呼吸器学会誌 6 ( 増刊 ) 156 - 156 2017年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap

▼全件表示

MISC

重症喘息バイオ製剤使用例における気道内粘液栓除去効果と気道壁肥厚に関する画像評価

室橋光太, 原悠, 田辺直也, 長澤遼, 林優介, 井澤亜美, 大津佑希子, 平田萌々, 上田傑, 田中克志, 久保創介, 藤井裕明, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 平井豊博, 金子猛

アレルギー 73 ( 6-7 ) 904 - 904 2024年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
気管支喘息(成人):臨床的寛解1 高齢者重症喘息における生物学的製剤による臨床的寛解の検討

室橋光太, 原悠, 丸毛聡, 田辺直也, 森田恭平, 塚本信哉, 船内敦司, 林優介, 高橋祥太, 西坂泰夫, 福井基成, 平井豊博

アレルギー 73 ( 6-7 ) 835 - 835 2024年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
喘息臨床的寛解重症喘息において併存症は臨床的寛解に影響しうるか

丸毛聡, 田辺直也, 塚本信哉, 船内敦司, 林優介, 高橋祥太, 石川遼一, 森田恭平, 吉村千恵, 室橋光太, 原悠, 福井基成, 金子猛, 平井豊博

日本呼吸器学会誌 13 ( 増刊 ) 214 - 214 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
びまん性肺疾患治療特発性肺線維症における抗線維化薬使用下での慢性呼吸不全死亡群と急性増悪発症群の臨床像の差異

室橋光太, 原悠, 藤井裕明, 長澤遼, 田上陽一, 青木絢子, 増田誠, 榎本達治, 松本裕, 渡邉恵介, 堀田信之, 小林信明, 工藤誠, 小倉高志, 金子猛

日本呼吸器学会誌 13 ( 増刊 ) 211 - 211 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
当院未治療閉塞性肺疾患患者におけるSingle-inhaler triple therapy(SITT)使用実態調査

室橋光太, 原悠, 長澤遼, 井澤亜美, 金子猛, 大津佑希子, 平田萌々, 堀田信之, 小林信明, 渡邉恵介, 藤井裕明, 田中克志, 久保創介, 村岡傑

日本呼吸器学会誌 13 ( 増刊 ) 275 - 275 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
重症喘息に対する生物学的製剤によるClinical Remissionと胸部CT所見の検討

塚本信哉, 丸毛聡, 田辺直也, 船内敦司, 森田恭平, 吉村千恵, 高橋祥太, 石川遼一, 室橋光太, 原悠, 林優介, 福井基成, 金子猛, 平井豊博

日本呼吸器学会誌 13 ( 増刊 ) 299 - 299 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
重症喘息における臨床的寛解の定義の検討

船内敦司, 丸毛聡, 田辺直也, 塚本信哉, 林優介, 高橋祥太, 石川遼一, 森田恭平, 吉村千恵, 室橋光太, 原悠, 福井基成, 金子猛, 平井豊博

日本呼吸器学会誌 13 ( 増刊 ) 299 - 299 2024年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
IgG4関連肺疾患におけるnew disease entityの考察

井口紗良, 藤井裕明, 原悠, 金子恵, 井澤亜美, 室橋光太, 田上陽一, 金子彩美, 染川弘平, 松本大海, 村岡傑, 田中克志, 青木絢子, 渡邊恵介, 堀田信之, 小林信明, 田中まりか, 奥寺康司, 金子猛

日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 184回・256回 12 - 12 2023年9月

　詳細を見る

記述言語：日本語出版者・発行元：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会

researchmap
喘息と気道・粘液気管支喘息患者における気道内粘液栓の臨床的意義

原悠, 藤井裕明, 室橋光太, 田上陽一, 井澤亜美, 金子恵, 村岡傑, 神巻千聡, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

アレルギー 72 ( 6-7 ) 881 - 881 2023年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
喘息と気道・粘液気管支喘息患者における気道内粘液栓の臨床的意義

原悠, 藤井裕明, 室橋光太, 田上陽一, 井澤亜美, 金子恵, 村岡傑, 神巻千聡, 青木絢子, 渡邉恵介, 堀田信之, 小林信明, 金子猛

アレルギー 72 ( 6-7 ) 881 - 881 2023年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
アレルギー・免疫疾患:臨床課題と希少症例(Clinical significance of eosinophilic phenotype in bronchiectasis)

小林信明, 福田信彦, 村岡傑, 井澤亜美, 金子彩美, 室橋光太, 田中克志, 青木絢子, 渡邉恵介, 堀田信之, 原悠, 金子猛

アレルギー 72 ( 6-7 ) 891 - 891 2023年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
Unexplained chronic coughとCough hypersensitivity syndromeの概念と対応—The concepts and treatment of unexplained chronic cough and cough hypersensitivity syndrome

室橋光太, 原悠

呼吸器内科 = Respiratory medicine / 呼吸器内科編集委員会編 44 ( 1 ) 116 - 120 2023年7月

　詳細を見る

記述言語：日本語出版者・発行元：東京 : 科学評論社

CiNii Books

CiNii Research

researchmap

その他リンク： https://ndlsearch.ndl.go.jp/books/R000000004-I033025192
当院における高齢者喘息患者におけるベンラリズマブの有効性と安全性の検討

染川弘平, 渡邉恵介, 金子猛, 小林信明, 原悠, 堀田信之, 田上陽一, 青木絢子, 室橋光太, 神巻千聡, 井澤亜美, 金子恵, 村岡傑

日本呼吸器学会誌 12 ( 増刊 ) 285 - 285 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
喘息診断・諸問題気管支喘息患者におけるMDCT mucus scoreの臨床的意義

室橋光太, 小松茂, 長澤遼, 渡邉恵介, 原悠, 小倉高志, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 200 - 200 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
IPFにおける重症度に応じた抗線維化薬治療期間と長期予後の関連性多施設共同後ろ向きコホート研究

平田萌々, 原悠, 藤井裕明, 室橋光太, 田上陽一, 長澤遼, 青木絢子, 増田誠, 榎本達治, 松本裕, 渡邉恵介, 堀田信之, 小林信明, 平居義裕, 工藤誠, 小倉高志, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 217 - 217 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
特発性肺線維症におけるGAPスコア毎のニンテダニブとピルフェニドンの効果と安全性に関する比較検討

藤井裕明, 原悠, 室橋光太, 田上陽一, 長澤遼, 青木絢子, 増田誠, 榎本達治, 松本裕, 渡邉恵介, 堀田信之, 小林信明, 工藤誠, 小倉高志, 金子猛

日本呼吸器学会誌 12 ( 増刊 ) 242 - 242 2023年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
抗癌剤治療中に開放性結核を発症した症例の検討

須藤いい那, 神巻千聡, 小林信明, 金子恵, 村岡傑, 田中克志, 田上陽一, 室橋光太, 青木絢子, 渡邊恵介, 堀田信之, 原悠, 金子猛

日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 182回・251回 24 - 24 2022年9月

　詳細を見る

記述言語：日本語出版者・発行元：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会

researchmap
生物学的製剤を要する慢性重症喘息患者におけるMDCT mucus scoreの変動に対する考察

藤井裕明, 原悠, 田上陽一, 青木絢子, 室橋光太, 神巻千聡, 渡邉恵介, 堀田信之, 小林信明, 金子猛

アレルギー 71 ( 6-7 ) 873 - 873 2022年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
当院における間質性肺疾患とテロメア長の関係性の検討

室橋光太, 大利亮太, 北村英也, 小倉高志, 萩原恵里, 小松茂, 馬場智尚, 関根朗雅, 奥田良, 織田恒幸, 中澤篤人, 丹羽崇, 池田慧, 田畑恵里奈, 酒寄雅史, 山谷昴史, 長澤遼, 鏑木翔太, 犬養舜, 山田翔

日本呼吸器学会誌 11 ( 増刊 ) 246 - 246 2022年4月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
COVID-19患者に対するコルチコステロイドの治療効果—Effects of corticosteroid in the treatment of COVID-19—特集 COVID-19の新知見

室橋光太, 池田慧, 小倉髙志

臨床免疫・アレルギー科 = Clinical immunology & allergology / 臨床免疫・アレルギー科編集委員会編 77 ( 3 ) 251 - 255 2022年3月

　詳細を見る

記述言語：日本語出版者・発行元：東京 : 科学評論社

CiNii Books

CiNii Research

researchmap

その他リンク： https://ndlsearch.ndl.go.jp/books/R000000004-I032018319
IPF治療薬の開発最新情報—Development update on IPF therapy

岡林比呂子, 北山貴章, 室橋光太, 佐藤陽三, 小倉髙志

呼吸器内科 = Respiratory medicine / 呼吸器内科編集委員会編 38 ( 6 ) 561 - 567 2020年12月

　詳細を見る

記述言語：日本語出版者・発行元：東京 : 科学評論社

CiNii Books

CiNii Research

researchmap

その他リンク： https://ndlsearch.ndl.go.jp/books/R000000004-I030806816
特発性肺線維症(IPF)患者における抗線維化薬内服期間と長期予後との関連性の検討(多施設共同研究)

青木絢子, 原悠, 室橋光太, 陳昊, 長澤遼, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛, 工藤誠, 平馬暢之, 榎本達治

日本呼吸器学会誌 9 ( 増刊 ) 153 - 153 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺炎急性増悪予後予測因子としてCharlson comorbidity index、血清LDH値、性別を用いたスコアリングシステムの検討

室橋光太, 原悠, 青木絢子, 陳昊, 長澤遼, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 工藤誠, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 301 - 301 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺炎急性増悪予後予測因子としてCharlson comorbidity index、血清LDH値、性別を用いたスコアリングシステムの検討

室橋光太, 原悠, 青木絢子, 陳昊, 長澤遼, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 工藤誠, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 301 - 301 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患における長期予後予測モデルの作成の試み

上田傑, 原悠, 室橋光太, 三枝祐輔, 柳生洋行, 長澤遼, 青木絢子, 陳昊, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 302 - 302 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患急性増悪における血清HO-1とチャールソン併存疾患指数(CCI)を組み合わせた予後予測モデルの有用性の検証

田上陽一, 原悠, 室橋光太, 青木絢子, 張田佳代, 陳昊, 長澤遼, 柳生洋行, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 199 - 199 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患急性増悪における血清D-dimerの臨床組織学的考察

長澤遼, 原悠, 室橋光太, 張田佳代, 松村雅仁, 川村飛翔, 柳生洋行, 青木絢子, 陳昊, 田中克志, 池田美彩子, 橋本恒, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 湯本健太郎, 渡邉恵介, 渡邊弘樹, 小林信明, 工藤誠, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 252 - 252 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
肺癌トランスレーショナル EGFR遺伝子変異陽性肺癌の腫瘍オルガノイドの作成とEGFR-TKI耐性の検討

藤本拓也, 片倉誠悟, 小林信明, 橋本恒, 田中克志, 井上玲, 長澤遼, 池田美彩子, 室橋光太, 陳昊, 増本菜美, 青木絢子, 中島健太郎, 湯本健太郎, 寺西周平, 渡邊弘樹, 渡邉恵介, 原悠, 金子猛

日本呼吸器学会誌 9 ( 増刊 ) 133 - 133 2020年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
肺癌患者における血清hemeoxygenase-1と予後に関する検討

井上玲, 原悠, 室橋光太, 橋本恒, 田中克志, 長澤遼, 池田美彩子, 陳昊, 青木絢子, 渡邊弘樹, 中島健太郎, 渡邉恵介, 増本菜美, 片倉誠悟, 湯本健太郎, 寺西周平, 小林信明, 山本昌樹, 工藤誠, 金子猛

肺癌 59 ( 6 ) 698 - 698 2019年11月

　詳細を見る

記述言語：日本語出版者・発行元：(NPO)日本肺癌学会

researchmap
高IgE症候群により反復する呼吸器感染症を起こした3例

柳生洋行, 長井賢次郎, 原悠, 金井亮憲, 池田美彩子, 室橋光太, 渡邊恵介, 小林信明, 佐藤隆, 金子猛

アレルギー 68 ( 8 ) 980 - 980 2019年9月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
結核診断におけるTBAg/PHA比の有用性および結果に影響する因子の検討

北堀弘大, 片倉誠悟, 小林信明, 井上玲, 金井亮憲, 柳生洋行, 室橋光太, 増本菜美, 中島健太郎, 湯本健太郎, 田代研, 寺西周平, 池田美彩子, 長井賢次郎, 渡邊恵介, 原悠, 佐藤隆, 山本昌樹, 工藤誠, 金子猛

神奈川医学会雑誌 46 ( 2 ) 268 - 268 2019年7月

　詳細を見る

記述言語：日本語出版者・発行元：神奈川県医師会

researchmap
肺外固形腫瘍を合併した肺Mycobacterium avium complex症例の検討

井上玲, 渡邉恵介, 金井亮憲, 柳生洋行, 池田美彩子, 室橋光太, 長井賢次郎, 若林綾, 原悠, 片倉誠悟, 増本菜美, 中島健太郎, 湯本健太郎, 寺西周平, 田代研, 小林信明, 佐藤隆, 金子猛

神奈川医学会雑誌 46 ( 2 ) 272 - 272 2019年7月

　詳細を見る

記述言語：日本語出版者・発行元：神奈川県医師会

researchmap
高IgE症候群により反復する呼吸器感染症を生じた3症例

徳田花子, 長井賢次郎, 原悠, 井上玲, 金井亮憲, 柳生洋行, 池田美彩子, 室橋光太, 片倉誠悟, 増本菜美, 湯本健太郎, 中島健太郎, 寺西周平, 田代研, 渡邊恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

神奈川医学会雑誌 46 ( 2 ) 269 - 269 2019年7月

　詳細を見る

記述言語：日本語出版者・発行元：神奈川県医師会

researchmap
敗血症性ショック急性呼吸促拍症候群を認めた肺結核の一例

池田美彩子, 原悠, 長井賢次郎, 室橋光太, 品田佳那子, 柳生洋行, 金井亮憲, 井上玲, 中島健太郎, 増本菜美, 片倉誠悟, 寺西周平, 田代研, 湯本健太郎, 渡邊恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

神奈川医学会雑誌 46 ( 2 ) 264 - 265 2019年7月

　詳細を見る

記述言語：日本語出版者・発行元：神奈川県医師会

researchmap
当院におけるT-SPOT.TB検査の現状

清水咲耶, 片倉誠悟, 小林信明, 井上玲, 金井亮憲, 柳生洋行, 室橋光太, 増本菜美, 中島健太郎, 湯本健太郎, 田代研, 寺西周平, 池田美彩子, 長井賢次郎, 渡邊恵介, 原悠, 佐藤隆, 金子猛

神奈川医学会雑誌 46 ( 2 ) 268 - 268 2019年7月

　詳細を見る

記述言語：日本語出版者・発行元：神奈川県医師会

researchmap
質量分析法により診断しえたMycobacterium lentiflavum肺感染症の1例

渡邉恵介, 金井亮憲, 室橋光太, 井上玲, 柳生洋行, 池田美彩子, 長井賢次郎, 原悠, 小林信明, 佐藤隆, 金子猛

気管支学 41 ( Suppl. ) S360 - S360 2019年6月

　詳細を見る

記述言語：日本語出版者・発行元：(NPO)日本呼吸器内視鏡学会

researchmap
呼気一酸化窒素検査の導入による咳嗽診療への影響

井上玲, 原悠, 熊谷英之, 金井亮憲, 柳生洋行, 池田美彩子, 室橋光太, 長井賢次郎, 渡邉恵介, 増本菜美, 片倉誠悟, 湯本健太郎, 中島健太郎, 寺西周平, 田代研, 小林信明, 佐藤隆, 金子猛

アレルギー 68 ( 4-5 ) 607 - 607 2019年5月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本アレルギー学会

researchmap
間質性肺炎急性増悪における全身ステロイド治療の予後への影響に関する検討

柳生洋行, 原悠, 室橋光太, 長井賢次郎, 池田美彩子, 品田佳那子, 金井亮憲, 井上玲, 増本菜美, 片倉誠悟, 湯本健太郎, 寺西周平, 中島健太郎, 田代研, 渡邉恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 196 - 196 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺疾患における予後予測スコアリングシステム確立の試み

室橋光太, 原悠, 長井賢次郎, 池田美彩子, 品田佳那子, 柳生洋行, 金井亮憲, 井上玲, 増本菜美, 片倉誠悟, 湯本健太郎, 寺西周平, 中島健太郎, 田代研, 渡邉恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 349 - 349 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
当院における免疫チェックポイント阻害薬による薬剤性肺障害の検討

金井亮憲, 小林信明, 柳生洋行, 井上玲, 室橋光太, 増本菜美, 片倉誠悟, 湯本健太郎, 中島健太郎, 寺西周平, 田代研, 池田美彩子, 長井賢次郎, 渡邉恵介, 若林綾, 原悠, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 269 - 269 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺炎における急性増悪発症予測因子の検討

増本菜美, 原悠, 室橋光太, 長井賢次郎, 池田美彩子, 品田佳那子, 柳生洋行, 金井亮憲, 井上玲, 片倉誠悟, 湯本健太郎, 寺西周平, 中島健太郎, 田代研, 渡邉恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 287 - 287 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
特発性間質性肺炎急性増悪と自己抗体陽性間質性肺炎急性増悪の臨床像の検討

増本菜美, 原悠, 室橋光太, 長井賢次郎, 池田美彩子, 品田佳那子, 柳生洋行, 金井亮憲, 井上玲, 片倉誠悟, 湯本健太郎, 寺西周平, 中島健太郎, 田代研, 渡邉恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 196 - 196 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
TBLBにて非特異性間質性肺炎(NSIP),器質化肺炎(OP),NSIP/OP overlap(NSIP/OP)所見を認めた症例の臨床像と予後因子の検討

池田美彩子, 原悠, 室橋光太, 長井賢次郎, 品田佳那子, 柳生洋行, 金井亮憲, 井上玲, 増本菜美, 片倉誠悟, 湯本健太郎, 寺西周平, 中島健太郎, 田代研, 渡邉恵介, 若林綾, 小林信明, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 197 - 197 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
活動性結核感染症と潜在性結核感染症の鑑別におけるTBAg/PHA値の有用性

片倉誠悟, 小林信明, 井上玲, 金井亮憲, 柳生洋行, 池田美彩子, 室橋光太, 増本菜美, 中島健太郎, 湯本健太郎, 田代研, 寺西周平, 長井賢次郎, 渡邉恵介, 若林綾, 原悠, 佐藤隆, 金子猛

日本呼吸器学会誌 8 ( 増刊 ) 171 - 171 2019年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
生検部位の決定にFDG-PETが有用であった再発性多発性軟骨炎の1例

木根佑奈, 渡邉恵介, 金井亮憲, 井上玲, 柳生洋行, 室橋光太, 池田美彩子, 長井賢次郎, 原悠, 小林信明, 佐藤隆, 金子猛

日本結核病学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 175回・233回 22 - 22 2019年2月

　詳細を見る

記述言語：日本語出版者・発行元：日本結核病学会関東支部学会・日本呼吸器学会関東地方会

researchmap
CTにて過敏性肺炎パターンを呈するニボルマブによる薬剤性肺障害が疑われた1例

井上玲, 長井賢次郎, 金井亮憲, 柳生洋行, 池田美彩子, 室橋光太, 渡邉恵介, 若林綾, 原悠, 増本菜美, 片倉誠悟, 湯本健太郎, 中島健太郎, 寺西周平, 田代研, 小林信明, 佐藤隆, 金子猛

日本結核病学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 175回・233回 24 - 24 2019年2月

　詳細を見る

記述言語：日本語出版者・発行元：日本結核病学会関東支部学会・日本呼吸器学会関東地方会

researchmap
癌性腹膜炎を併発した原発性肺癌3例－文献レビューも含めて－

小俣, 亜梨沙, 原, 悠, 室橋, 光太, 長井 , 賢次郎, 池田, 美彩子, 柳生, 洋行, 金井, 亮憲, 井上, 玲, 増本, 菜美, 片倉, 誠悟, 湯本, 健太郎, 寺西, 周平, 中島, 健太郎, 田代, 研, 渡邉 , 恵介, 若林, 綾, 小林, 信明, 佐藤, 隆, 金子, 猛

横浜医学 70 ( 1 ) 19 - 23 2019年1月

　詳細を見る

記述言語：日本語出版者・発行元：横浜市立大学医学会

原発性肺癌の癌性腹膜炎の併発頻度は1%前後と極めて低い．今回我々は，同病態を認めた3例を経験したため，その臨床経過について，文献的考察を加えて報告する．平均年齢65歳，男性2例と女性1例．いずれも腺癌で，1例でEGFR T790変異陽性乳び腹水を認めた．全生存期間は36.7か月，腹腔内病変確認からの生存期間は3.7か月であり，癌性腹膜炎併発後に病態が急速に悪化することが予想された．

CiNii Research

researchmap

その他リンク： http://id.nii.ac.jp/1246/00001679/
TBLBにて非特異性間質性肺炎(NSIP),器質化肺炎(OP)の所見を認めた症例の臨床像の比較検討

池田美彩子, 原悠, 長井賢次郎, 品田佳那子, 室橋光太, 湯本健太郎, 渡邉恵介, 中島健太郎, 木村泰浩, 牛尾良太, 田代研, 若林綾, 篠田雅宏, 佐藤隆, 新海正晴, 金子猛

気管支学 40 ( Suppl. ) S245 - S245 2018年5月

　詳細を見る

記述言語：日本語出版者・発行元：(NPO)日本呼吸器内視鏡学会

researchmap
術後縫合糸の真菌感染を気管支鏡検査にて診断し得た1例

井澤亜美, 品田佳那子, 原悠, 室橋光太, 池田美彩子, 湯本健太郎, 中島健太郎, 牛尾良太, 木村泰浩, 長井賢次郎, 田代研, 渡邉恵介, 篠田雅宏, 佐藤隆, 新海正晴, 金子猛

気管支学 40 ( 3 ) 274 - 274 2018年5月

　詳細を見る

記述言語：日本語出版者・発行元：(NPO)日本呼吸器内視鏡学会

researchmap
当院で経験した高齢者薬剤誤嚥による気管支異物の2症例

加濃大貴, 池田美彩子, 品田佳那子, 室橋光太, 湯本健太郎, 長井賢次郎, 渡邉恵介, 篠田雅宏, 原悠, 佐藤隆, 新海正晴, 金子猛

気管支学 40 ( 3 ) 275 - 276 2018年5月

　詳細を見る

記述言語：日本語出版者・発行元：(NPO)日本呼吸器内視鏡学会

researchmap
当院におけるEGFR遺伝子変異陽性非小細胞肺がん患者の再生検の実情

長井賢次郎, 原悠, 品田佳那子, 室橋光太, 成田篤哉, 池田美彩子, 佐々木寿, 牛尾良太, 木村泰浩, 中島健太郎, 湯本健太郎, 田代研, 柴田祐司, 渡邉恵介, 長倉秀幸, 篠田雅宏, 佐藤隆, 新海正晴, 金子猛

日本呼吸器学会誌 7 ( 増刊 ) 248 - 248 2018年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺炎急性増悪予後予測因子としてのCharlson comorbidity indexの有用性の検討

室橋光太, 原悠, 長井賢次郎, 品田佳那子, 池田美彩子, 中島健太郎, 木村泰浩, 柴田祐司, 田代研, 湯本健太郎, 渡邉恵介, 篠田雅宏, 佐藤隆, 工藤誠, 新海正晴, 金子猛

日本呼吸器学会誌 7 ( 増刊 ) 269 - 269 2018年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
COPDにおける血清ヘムオキシゲナーゼ-1(HO-1)値に関する検討

湯本健太郎, 原悠, 室橋光太, 品田佳那子, 池田美彩子, 中島健太郎, 木村泰浩, 牛尾良太, 柴田祐司, 田代研, 長井賢次郎, 渡邉恵介, 篠田雅宏, 小林信明, 山本昌樹, 佐藤隆, 工藤誠, 新海正晴, 金子猛

日本呼吸器学会誌 7 ( 増刊 ) 293 - 293 2018年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
間質性肺炎(IP)における予後予測マーカーとしての血清ヘムオキシゲナーゼ-1(HO-1)の有用性に関する検討

品田佳那子, 原悠, 長井賢次郎, 室橋光太, 池田美彩子, 佐々木寿, 湯本健太郎, 中島健太郎, 牛尾良太, 木村泰浩, 柴田祐司, 田代研, 渡邉恵介, 篠田雅宏, 佐藤隆, 川名明彦, 新海正晴, 金子猛

日本呼吸器学会誌 7 ( 増刊 ) 198 - 198 2018年3月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本呼吸器学会

researchmap
呼吸困難—特集呼吸器救急診療ブラッシュアップ : 自信をもって対応できる ; 呼吸器徴候からみた救急診療

室橋光太, 原悠, 金子猛

呼吸器ジャーナル 66 ( 1 ) 15 - 20 2018年

　詳細を見る

記述言語：日本語出版者・発行元：東京 : 医学書院

CiNii Books

CiNii Research

researchmap

その他リンク： https://ndlsearch.ndl.go.jp/books/R000000004-I028799003
自然軽快した両肺尖部ブラ内感染の一例

室橋光太, 井上美代, 都丸光二, 宮沢直幹

神奈川医学会雑誌 44 ( 1 ) 126 - 126 2017年1月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
肺炎像を呈した感染性心内膜炎の2例

室橋光太, 井上美代, 都丸公二, 宮沢直幹

神奈川医学会雑誌 43 ( 2 ) 369 - 369 2016年7月

　詳細を見る

記述言語：日本語出版者・発行元：(公社)神奈川県医師会

researchmap
EUS-FNAが診断に有用であった胃癌吻合部再発の1例

室橋光太, 三輪治生, 杉森一哉, 戸塚雄一郎, 石井ゆにば, 亀田英里, 石井寛裕, 金子卓, 大島貴, 粉川敦史, 沼田和司, 國崎主税, 田中克明, 前田愼

Progress of Digestive Endoscopy 85 ( 1 ) 88 - 89 2014年

　詳細を見る

記述言語：日本語出版者・発行元：一般社団法人日本消化器内視鏡学会関東支部

DOI： 10.11641/pde.85.1_88

DOI： 10.11641/pde.103.1_81_references_DOI_RcLMmIhAuIPH4EHI7fnGOLIzBcI

CiNii Research

researchmap

▼全件表示